Rockefeller University

Digital Commons @ RU
Student Theses and Dissertations

2014

Mechanism and Evolutionary Origins of HIV-1
Virion Entrapment by Tetherin
Siddarth Venkatesh

Follow this and additional works at: http://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
Recommended Citation
Venkatesh, Siddarth, "Mechanism and Evolutionary Origins of HIV-1 Virion Entrapment by Tetherin" (2014). Student Theses and
Dissertations. Paper 220.

This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact mcsweej@mail.rockefeller.edu.

MECHANISM AND EVOLUTIONARY ORIGINS OF HIV-1
VIRION ENTRAPMENT BY TETHERIN

A Thesis Presented to the Faculty of
The Rockefeller University
in Partial Fulfillment of the Requirements for
the degree of Doctor of Philosophy

by
Siddarth Venkatesh
June 2014

 Copyright by Siddarth Venkatesh 2014

MECHANISM AND EVOLUTIONARY ORIGINS OF HIV-1 VIRION
ENTRAPMENT BY TETHERIN
Siddarth Venkatesh, Ph.D.
The Rockefeller University 2014
The cellular restriction factor, tetherin, prevents HIV-1 and other enveloped virus
particles from being disseminated into the extracellular milieu by infiltrating their
envelopes and by physically crosslinking them to the cell surface. However, the
mechanisms underlying virion retention have not yet been fully delineated. In this
body of work, we employed biochemical assays and engineered tetherin proteins
to demonstrate conclusively that virion tethers are composed of the tetherin
protein itself, and to elucidate the configuration and topology that tetherin adopts
during virion entrapment. We demonstrated that tetherin dimers adopt an “axial”
configuration,

in

which

pairs

of

transmembrane domains or pairs of

glycosylphosphatidyl inositol anchors are inserted into assembling particles,
while the remaining pair of membrane anchors remains embedded in the infected
cell membrane. We used quantitative western blotting to determine that a few
dozen tetherin dimers are used to trap each virion particle, and that there is ~3-5
fold preference for the insertion of glycosylphosphatidyl inositol anchors rather
than transmembrane domains into tethered virions. Cumulatively, these results
demonstrated

that

axially

configured

tetherin

homodimers

are

directly

responsible for trapping virions at the cell surface. We propose that insertion of
glycosylphosphatidyl inositol anchors may be preferred so that effector functions

that require exposure of the tetherin N-terminus to the cytoplasm of infected cells
are retained.
Allied to these efforts, we also endeavored to determine the evolutionary origins
of tetherin. We used computational and biochemical approaches to build a case
that tetherin arose via duplication of the neighboring PLVAP/PV1 gene. The PV1
and tetherin genes are located adjacent to each other in eutherian mammals and
encode proteins with a shared and relatively unusual overall architecture.
Phylogenetic analyses provided evidence that tetherin is ~147 MY old and that it
has evolved under positive selection. Conversely, PV1 is ~400 MY old and has
evolved under purifying selection in therian mammals. Using biochemical assays,
we demonstrated that PV1 can be endowed with antiviral activity against HIV-1
when it is engineered to encode a C-terminal GPI anchor. Although we did not
detect any sequence homology between PV1 and tetherin, in silico evolution
experiments indicated that it is possible to evolve sequences from an ancestral
PV1 sequence that bear no significant homology to contemporary PV1, after
simulating the evolutionary processes that contributed to the emergence of
tetherin. We found that genes encoding proteins with PV1/tetherin-like
architecture are quite rare in the human and mouse genomes, and that the
majority of these genes that are adjacent to each other likely arose via gene
duplication. Moreover, some, but not all, PV1/tetherin-like proteins have the
intrinsic ability to trap virions, when appended with a GPI anchor. Finally, we
analyzed the organization of genes in the PV1 locus from amphibians to
eutherian mammals and identified an ancestral synteny block that supports a

model in which tetherin arose from a PV1 duplication, that occurred between the
times that monotremes and marsupials diverged from other mammals (~166-147
MYA). Cumulatively, these findings suggest that tetherin arose by gene
duplication of PV1 and exemplify the remarkable capacity of our genomes to
innovate antiviral factors from pre-existing genetic raw material.
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Chapter I Introduction
At present, acquired immunodeficiency syndrome (AIDS) is one of the most
devastating global pandemics in human history, and has been responsible for
claiming more than an estimated 36 million lives worldwide (UNAIDS, 2013). This
is quite remarkable, given that its etiologic agent, human immunodeficiency virus1 (HIV-1), was only recently identified to be a human pathogen (Barre-Sinoussi et
al., 1983). Infected individuals progress to AIDS and eventually succumb to
opportunistic infections or tumors as a consequence of a near-complete erosion
of their immune systems. The advent of highly active antiretroviral therapy
(HAART) marked a turning point in the epidemic, and resulted in reduced
morbidity and mortality in First World countries. However, it is sobering to note
that most infected people in the Third World still have limited (or no) access to
HAART (Richman et al., 2009). In spite of prevention strategies and efforts, the
numbers of new infections continue to climb steadily. Also, AIDS patients who
are noncompliant become resistant to antiretroviral therapy due to the acquisition
of mutations; thus there is an impetus to discover new drug targets and
therapeutic modalities.
HIV-1 is a member of a family of enveloped diploid RNA viruses called
retroviridae. All retroviruses establish persistent infection in mammalian species
by depositing copies of their genomic DNA into the chromosomes of host cells
(Temin, 1964). HIV-1 belongs to the genus of retroviruses called lentiviruses,
which are characterized by the unusually long time that it takes between infection
and manifestation of chronic disease. Many of the known lentiviruses are
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transmitted between individuals in a horizontal manner, i.e. via extracellular
virions. In certain instances, however, they are inserted into the germline as
proviruses and can be inherited vertically in a Mendelian fashion (Katzourakis et
al., 2007; Martin et al., 1981a; Martin et al., 1981b). HIV-1 is also vertically
transmitted from a HIV-positive mother to her child during pregnancy, delivery
and breastfeeding.
In general, lentiviruses share many features such as their genetic architecture,
particle (or virion) morphology, and life cycles. All retroviruses encode three
genes: gag, pol, and env, which direct the production of the structural, enzymatic
and envelope components of the virus respectively. In addition, lentiviruses also
encode the so-called “accessory genes” that are necessary for efficient
replication in certain cell types, but are dispensable in others. HIV-1 also
encodes the Tat and Rev proteins that regulate transcription from the viral LTR
and export of unspliced and incompletely spliced transcripts to the cytoplasm,
respectively.
A lentiviral particle typically comprises of a viral core of approximately 1000-5000
copies of the capsid (CA) protein, which have the propensity of self-assembling
into a stable lattice (Briggs et al., 2004; Piatak et al., 1993; Zhu et al., 2003).
Protected within this structure are two copies of the viral RNA genome along with
an assortment of virion-associated proteins such as matrix (MA), capsid (CA),
nucleocapsid (NC), protease (PR), reverse transcriptase (RT), integrase (IN) and
viral protein R (Vpr) (Kohl et al., 1988). As such, the core is itself confined within
a spherical lipid bilayer that serves as an outer shell, with MA being closely
-2-

associated with the inner leaflet of the lipid bilayer. Several copies of the viral
envelope protein (Env) are embedded within the bilayer and extend outwards to
interact with receptor molecules on cell surfaces.
A comprehensive treatment of the lentiviral life cycle is not feasible because of
space constraints; however, a few simple concepts will be presented in the next
section.

Overview of the lentiviral life cycle
The lentiviral life cycle (Figure 1.1) begins with the adhesion of virions to target
cells by relatively non-specific interactions with various molecules such as
integrins or DC-SIGN that are expressed on the cell surface (Cicala et al., 2009;
Geijtenbeek et al., 2000).Thereafter, the Env molecules bind a specific receptor
molecule on the target cell, and it is the specificity of this interaction that governs
host range and tissue tropism. In the case of HIV-1, the Env protein is a trimer of
gp120 and gp41 heterodimers. The gp120 subunit is the surface protein and the
gp41 is a transmembrane protein (McCune et al., 1988). The gp120 subunit
binds the primary receptor CD4 (Maddon et al., 1986; McDougal et al., 1986),
which prompts conformational changes in Env, facilitating the engagement of the
coreceptors CCR5 or CXCR4 (Alkhatib et al., 1996; Choe et al., 1996; Deng et
al., 1996; Dragic et al., 1996; Feng et al., 1996) (Figure 1.1).
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Figure 1.1. Overview of the lentiviral life cycle. Refer text for details.
Disclaimer: This figure was kindly provided by Theodora Hatziioannou (Aaron
Diamond AIDS Research Center, NY).
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Next, a series of structural rearrangements within the transmembrane region of
Env exposes the hitherto concealed gp41 fusion peptide, which inserts into the
target cell membrane and forms a six-helix bundle (Chan et al., 1997;
Weissenhorn et al., 1997). Folding of the gp41 molecule to form a
thermodynamically favorable state wherein its termini are at the same ends of the
folded molecule, drives fusion of the two lipid bilayers. This is believed to
proceed via a hemifusion stalk intermediate in which the proximal leaflets merge,
and ultimately leads to the formation of a pore (Eckert and Kim, 2001). However,
this is a relatively small opening, and pore dilation occurs via poorly understood
mechanisms. The pore serves as the conduit through which the viral core is
delivered into the cytoplasm (Wilen et al., 2012).
What follows next is a series of nebulous events popularly referred to as
“uncoating” (Figure 1.1), wherein the capsid lattice begins a process of
disassembly as it traverses through the cytoplasm en route to the nucleus
(McDonald et al., 2002; Zhang et al., 2000). This sets the stage for the first of two
steps that are peculiar to the retroviral life cycle, i.e. the generation of linear
double stranded DNA (dsDNA) from the single-stranded RNA genome via the
action of the viral enzyme reverse transcriptase (RT) (Baltimore, 1970; Mizutani
et al., 1970) (Figure 1.1). The biochemical mechanisms that underlie the process
of reverse transcription are quite well established (Hu and Hughes, 2012).
Interestingly, lentiviral RTs have evolved to be processive even under low
concentrations of deoxyribonucleotides (dNTPs), so that they can infect a wide
range of cell types (Diamond et al., 2004; Lahouassa et al., 2012). The nascent
-5-

dsDNA and associated enzymes form a preintegration complex (PIC) that
migrates toward the nucleus by engaging the cellular actin cytoskeleton network
(Bowerman et al., 1989; Miller et al., 1997). Lentiviral PICs are ushered into the
nucleoplasm through nuclear pore complexes; hence they are capable of
infecting non-dividing cells (Bukrinsky et al., 1992; Lewis et al., 1992) (Figure
1.1). In contrast, many other retroviruses must wait for the breakdown of the
nuclear envelope during mitosis to access chromosomal DNA, and thus depend
on the cell cycle for establishing a productive infection (Bieniasz et al., 1995; Roe
et al., 1993).
Within the nucleus, the viral enzyme integrase (IN) catalyzes the transesterification reactions that insert the viral dsDNA into the host genome (Brown
et al., 1987; Fujiwara and Mizuuchi, 1988; Goff, 1992; Roth et al., 1989) (Figure
1.1). Integration is essentially irreversible and allows the “genomic intruder” to
persist as provirus for the lifetime of the cell. Once integrated, the proviral DNA is
virtually indistinguishable from host DNA, and the host transcriptional machinery
generates viral transcripts that have all the typical attributes of cellular mRNAs.
Retroviruses tend to vary in their preference for integration sites, and HIV-1 has a
preference for integrating into active transcriptional units (Craigie and Bushman,
2012; Schroder et al., 2002; Wu et al., 2003).
The next phase of the life cycle, i.e. gene expression, is regulated by the Tat and
Rev proteins. The Tat protein is responsible for transactivation of LTR-driven
gene expression, and Rev mediates the export of the unspliced and incompletely
spliced transcripts to the cytoplasm (Dayton et al., 1986; Fisher et al., 1986;
-6-

Laspia et al., 1989; Rice and Mathews, 1988; Sodroski et al., 1986; Sodroski et
al., 1985a; Sodroski et al., 1985b). At first, basal levels of LTR activity drive the
generation of low levels of full-length transcripts. Thereafter, HIV-1 transcripts
undergo a complex splicing program to produce the full range of mRNAs that are
needed to encode the viral proteins. Note that the unspliced ~9-kb, incompletely
spliced ~4-kb and completely spliced ~1.8-kb mRNAs are produced even at early
stages of transcription, but in the absence of Rev, the longer transcripts are
retained in the nucleus where they are eventually degraded by RNA surveillance
mechanisms (Karn and Stoltzfus, 2012; Pollard and Malim, 1998). In contrast,
the short completely spliced ~1.8-kb mRNAs are shuttled out of the nucleus and
encode the three early gene products, i.e. Tat, Rev and Nef. The Tat protein then
stimulates transcription by binding the viral transactivator response (TAR)
element situated in the repeat (R) region of the mRNA transcript in the nucleus
(Berkhout et al., 1989; Muesing et al., 1987). This results in phosphorylation of
the RNA polymerase II C-terminal domain that results in enhanced processivity
on the proviral DNA template and multi-fold enhancement in levels of the fulllength transcript (Bieniasz et al., 1999; Parada and Roeder, 1996).
When the levels of the Rev protein in the nucleus exceed a certain threshold,
Rev molecules bind cooperatively to the Rev response element (RRE) that is
present in the unspliced ~9-kb and incompletely spliced ~4-kb mRNAs, and
shuttle them out to the cytoplasm (Malim et al., 1989; Pollard and Malim, 1998).
The full-length mRNAs are either translated to yield the ~55-kDa Gag and ~160kDa Gag-Pol precursors, or are assembled into progeny virions as genomes
-7-

(Jouvenet et al., 2008; Jouvenet et al., 2006; Jouvenet et al., 2009b) (Figure 1.1).
Intriguingly, in most retroviruses, the Gag-Pol precursor is translated as a result
of programmed frameshifting at a uridine-rich (UUUUUUA) slippery sequence
before the Gag stop codon (Jacks et al., 1988; Yoshinaka et al., 1985a, b).
Importantly, this event only occurs about 1 in 20 translation events, resulting in
an optimal stoichiometry of the Gag:Gag-Pol precursors.
The ~4-kb mRNAs are translated to yield the other late gene products, i.e. Vpu,
Vpr, Vif and Env. The Env glycoprotein is inserted cotranslationally into the ER
and is extensively glycosylated and assembled as trimers during anterograde
transport to the plasma membrane. Moreover, it is processed by the cellular
protease furin in the Golgi compartments to generate the mature gp120 and gp41
subunits, and then delivered to the plasma membrane via the secretory pathway
(Goff, 2007; Sundquist and Krausslich, 2012).
The assembly and budding of extracellular virions is an intricate process and is
mediated by the Gag polyprotein (Figure 1.1). Remarkably, ectopic expression of
the multifunctional Gag protein in a host cell is sufficient for the assembly and
release of immature virus-like particles (VLPs). The amino-terminal domain of
Gag, known as p17 matrix (MA), is responsible for plasma membrane targeting,
mainly via interactions between a string of basic residues near the amino
terminus with plasma membrane-specific phospholipids PI(4,5)P2 (Bieniasz,
2009). This binding event exposes a myristic acid modification at the N-terminus
of Gag molecules which tethers them stably to the inner leaflet of the plasma
membrane (Dalton et al., 2005; Paillart and Gottlinger, 1999; Zhou et al., 1994).
-8-

The p24 CA protein mediates homo-oligomerization, and as mentioned earlier,
condenses upon maturation to form the virion core (Borsetti et al., 1998). The p7
nucleocapsid (NC) protein traps genomic RNA dimers during particle assembly
via interactions between its zinc finger motif, and a packaging motif (ψ) that is
present on the full-length transcripts (D'Souza and Summers, 2005). The
carboxy-terminal p6 domain mediates the severing of the thin cytoplasm-filled
stalk that separates the viral and cellular membranes by usurping the cellular
ESCRT pathway (Martin-Serrano and Neil, 2011). It is well known that
retroviruses encode small peptide motifs known as late-budding (L) domains that
are essential for this process (Garrus et al., 2001; Gottlinger et al., 1991; MartinSerrano et al., 2001; Parent et al., 1995; Puffer et al., 1997; Wills et al., 1994;
Yasuda and Hunter, 1998; Yuan et al., 2000). In HIV-1, these domains bind
Tsg101 (a component of ESCRT-I) and ALIX (an ESCRT-I and ESCRT-IIIbinding protein) (Bieniasz, 2006). L domain mutants fail to complete the final
scission step in budding, thus resulting in clusters of immature virions whose
membranes are continuous to the cell membrane, in a manner reminiscent of
“beads on a string” (Gottlinger et al., 1991). Importantly, late domains require the
Class E vacuolar protein sorting (VPS) pathway to release virions (Bieniasz,
2006; Garrus et al., 2001; Martin-Serrano et al., 2005; Strack et al., 2003).
The maturation of virions requires proteolytic cleavage of the Gag and Gag-Pol
precursors by the viral enzyme PR to yield the structural (MA, CA, NC and p6)
and enzymatic (PR, IN, RT) proteins (Kohl et al., 1988) (Figure 1.1). The timing
of this event is linked to the activation of protease, which may be induced by the
-9-

oligomerization of Gag-Pol precursors within the virion. Thus, the mature virion
diffuses into the extracellular milieu and begins a new cycle of infection.
In turn, cells have erected rather formidable barriers to guard themselves against
viral invasion. We provide an overview of these defense measures in the next
section.

Restriction factors: an “intrinsic” immune system in host cells
Many examples are found in nature wherein antagonistic co-evolution results in
rapid adaptation of genes, physiology and behavior (Blanco-Melo et al., 2012).
Classic examples include those involving relationships between parasites and
hosts, or predators and prey. The invasion of host cells by viruses represents
another example of an antagonistic evolutionary struggle. Because viral
infections are often detrimental to host survival and reproduction, host cells have
evolved numerous defense mechanisms to sense, evade, and defend
themselves against a variety of viral infections. In animal cells, the sensing of
viruses by pattern recognition receptors leads to interferon production and
signaling, which induces the expression of hundreds of interferon-stimulated
genes (ISGs) in infected and bystander cells (Schoggins and Rice, 2011). Among
these are several classes of autonomously acting proteins that are popularly
termed “restriction factors”, and are considered to comprise an “intrinsic” immune
system (Bieniasz, 2004) or a specialized arm of conventional innate immunity.
There are five currently known families of restriction factors that target HIV-1 and
-10-

other primate lentiviruses: the APOBEC3 proteins (Sheehy et al., 2002), TRIM5
proteins (Stremlau et al., 2004), Tetherin (Neil et al., 2008; Van Damme et al.,
2008), SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011) and Mx2 (Goujon et
al., 2013; Kane et al., 2013; Liu et al., 2013). These proteins inhibit the replication
of viruses which then adapt to evade and defend themselves against this form of
host immunity. In turn, five classes of primate lentivirus proteins: Vif (Sheehy et
al., 2002), Vpu (Neil et al., 2008; Van Damme et al., 2008), Nef (Jia et al., 2009;
Zhang et al., 2009), Vpx (Hrecka et al., 2011; Laguette et al., 2011) and Env
(Gupta et al., 2009b; Le Tortorec and Neil, 2009) have evolved the ability to
antagonize a specific antiviral protein. In this way, antagonistic conflict begets
defense and counter defense measures, while recursively shaping host and viral
functions and genomes.
Restriction factors often possess certain attributes that differentiate them from
most other gene products (Malim and Bieniasz, 2012). Importantly, only those
gene products that directly engage viruses and inhibit their replication are
restriction factors. Specifically, they (i) are dominantly and autonomously acting
proteins that exhibit antiviral activity in simple cell-culture based assays, (iii) are
often constitutively expressed in some cell types, but are sometimes induced by
the expression of interferons, (iv) employ unique and unanticipated mechanisms
to inhibit specific processes in viral replication, (v) have unusually diverse amino
acid sequences as a consequence of antagonistic co-evolution with viruses, and
(vi) are often (but not always) antagonized by viral accessory proteins.
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Restriction factors are autonomous inhibitors of viral replication
In general, the antiviral restriction factors that have been identified thus far act as
self-sufficient entities, rather than as components of complex pathways.
Moreover, they act in a cell-autonomous fashion, i.e. their activity is evident in
simple cell-culture based viral replication or infectivity assays. Thus, their
existence was indicated by early studies that defined cell lines to be “permissive”
or “non-permissive”, depending on whether wild type or mutant viral strains could
efficiently replicate therein (Malim and Bieniasz, 2012). Often, cell fusion
experiments between permissive and non-permissive cell lines demonstrated
that heterokaryons that contained the contents of both cells exhibited the
restrictive phenotype, suggesting a dominant mode of action for putative
restriction factors (Malim and Bieniasz, 2012). Sometimes, mutant viruses
lacking a particular accessory gene failed to complete particular steps in the viral
life cycle in restrictive cell lines, and it was posited that the accessory gene was
required to antagonize an unknown inhibitor. These concepts underlined the
design of experiments that established the identification of several restriction
factors. In each case, expression of a single gene could convert the phenotype of
a cell line from permissive to non-permissive (Hrecka et al., 2011; Laguette et al.,
2011; Neil et al., 2008; Sheehy et al., 2002; Stremlau et al., 2004; Van Damme et
al., 2008).
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Restriction factors are constitutively expressed or induced by interferons
Adaptive immunity differs from innate immunity in various respects (Medzhitov,
2007). One key difference is the rapidity with which restriction factors can exert
their effects. T- and B- lymphocyte receptor diversity is generated via somatic
recombination, meaning that only tiny numbers of cells with antiviral potential are
present at the onset of a new infection. Effector cells are clonally expanded upon
exposure to the pathogen, requiring several days to weeks to accumulate
sufficient numbers to mount an effective adaptive immune response. In contrast,
fully active forms of restriction factors are encoded in the germ line and are
sometimes constitutively expressed. Indeed, prototypical human antiretroviral
restriction factors, i.e. APOBEC3G and TRIM5, were found to be constitutively
expressed in cell types targeted by primate lentiviruses, leading to the notion that
cells are resistant to infection in the apparent absence of any prior exposure or
signaling event (Bieniasz, 2004). The expression of another restriction factor,
tetherin, was stimulated upon the expression of interferons, indicating that it
constituted an antiviral response. While it was subsequently shown that each of
the known primate lentivirus restriction factors could be induced by interferon in
some cell types, IFN-induction is not essential to observe profound antiviral
activities in cells.
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Restriction factors have diverse mechanisms of action
In the case of adaptive immune responses and antiviral drugs that target viral
proteins, resistance is most often acquired through one or a few amino acid
substitutions that prevent recognition by the immune system and drugs. Like
antiretroviral drugs, restriction factors target specific steps in the HIV-1 life cycle,
but unlike antiretroviral drugs, do so in a way that makes it difficult for HIV-1 to
evolve resistance to the inhibitor through simple evasive mutations. In fact, these
proteins directly inhibit the replication of viruses via unanticipated, diverse and
remarkably elegant mechanisms of action (Figure 1.2).
Some members of the APOBEC3 proteins (APOBEC3F/G/H) inhibit HIV-1 by
infiltrating newly assembled virions and cause extensive deamination of
deoxycytidines in the nascent complementary DNA (cDNA) strand in target cells
during reverse transcription (Figures 1.2 and 1.3). Consequently, there is an
accumulation of deleterious deoxyguanine-to-deoxyadenine mutations in the viral
genome (Refsland and Harris, 2013). The Tripartite motif containing 5 isoform α
(TRIM5α) protein targets the incoming capsid protein prior to reverse
transcription, and triggers premature uncoating and/or capsid degradation (Sastri
and Campbell, 2011) (Figure 1.2). Tetherin is a dual-anchored transmembrane
protein that inhibits enveloped virions at the cell surface, thus preventing their
dissemination (Neil, 2013) (Figure 1.2). The SAM- and HD-domain containing
protein 1 (SAMHD1) is an enzyme with triphosphohydrolytic activity that inhibits
HIV-1 replication primarily by depleting intracellular nucleotide pools and
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Figure 1.2. Restriction factors directly inhibit the replication of HIV and
SIVs. The mechanisms by which restriction factors directly act upon various
stages of the retroviral replication cycle are depicted. The restriction factors are
indicated as red figures and the APOBEC3-mediated hypermutation of the viral
genome is indicated as red wavy lines. Refer text for details.
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Figure 1.3. Mechanism of the antiviral activity of the APOBEC3 family of
proteins. The APOBEC3F/G/H proteins catalyze extensive deoxycytidine
deamination (i.e. C to U mutations) in the nascent complementary DNA strand
that results in the accumulation of deoxyguanine-to-deoxyadenine mutations in
the viral genome. Such hypermutation is lethal as it results in the accumulation of
stop codons and aberrant splicing events in the viral genome.
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inhibiting reverse transcription (Sze et al., 2013) (Figure 1.2). The myxovirus
resistance 2 (Mx2) protein inhibits HIV-1 replication by inhibiting nuclear import
pathways, or by destabilizing viral DNA within the nucleus (Goujon et al., 2013;
Kane et al., 2013; Liu et al., 2013) (Figure 1.2). While the other restriction factors
directly interact with viral components (such as genome, capsid, and lipid
envelope), SAMHD1 has an indirect antiviral effect by regulating the
concentrations of intracellular nucleotide pools.

Antagonism of restriction factors by viral accessory genes
Presumably because they target steps of the viral replication cycle that are
immutable, and are hence difficult to escape via simple evasive mutations, the
mechanisms employed by restriction factors often provide an impetus for the
virus to evolve new strategies to counter the inhibition. In general, these
specialized countermeasures involve binding of the restriction factor by a viral
protein, followed by its removal from the cell, or sequestration to a subcellular
location where it can no longer execute its antiviral activity. During antagonism,
viral proteins often exploit the normal cellular degradation or transport machinery.
For example, Vif proteins bind to a number of APOBEC3 proteins and induce
their polyubiquitination and degradation by recruiting a cellular ubiquitin ligase
complex composed of cullin5, elongins B and C, and Rbx2 (Yu et al., 2003). A
similar mechanism is employed by SIV Vpr and Vpx proteins to eliminate
SAMHD1 from cells, although in this case, Vpr and Vpx are brought into a newly
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Figure 1.4. Counteraction of restriction factors by viral accessory genes.
The mechanisms by which restriction factors are antagonized are depicted. The
evasive mutations in the capsid protein that confer resistance to TRIM5 and Mx2
are indicated as brown circles. Restriction factors and their cognate antagonists
are indicated in red and green figures respectively. Cellular complexes that are
recruited by the antagonists are indicated in black lettering.
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infected cell as a component of the incoming virion. They do so by recruiting a
cullin4A-based ubiquitin ligase complex through a DDB1–DCAF1 adaptor
(Schrofelbauer et al., 2007). Simultaneous Vpr or Vpx binding to SAMHD1 leads
to SAMHD1 ubiquitination and degradation by proteasomes (Hrecka et al., 2011;
Laguette et al., 2011). Interestingly, three different lentiviral proteins (Vpu, Nef
and Env) have evolved the ability to antagonize tetherin. This topic will be dealt
with in greater detail in an upcoming section.

Restriction factors have evolved under positive selection
It is likely that antagonistic coevolution of interactions between viruses and their
hosts constitute a major driver of evolutionary change in both groups. Restriction
factor variants that confer a fitness advantage to an individual are selected by
viral infections, and become fixed in the host population. The reduction in viral
fitness in the newly adapted host provides the impetus for the selection of viral
variants that have mutations or new functions that relieve restriction and restore
fitness. Iterative cycles of this genetic conflict constitute a molecular “arms race”
and often result in intense Darwinian pressure to explore sequence space at the
interaction surfaces of restriction factors and their viral antagonists (Blanco-Melo
et al., 2012) (Figure 1.5).
A molecular arms race between protein-coding genes often means that
mutations that change the amino acid sequence (non-synonymous mutations)
are fixed more frequently than those that do not (synonymous mutations)
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Figure 1.5. Genetic conflict between the tetherin proteins in simian cells
and the Nef proteins encoded by SIVs. The tetherin proteins in simian cells are
antagonized by the SIV Nef proteins via a motif in the tetherin cytoplasmic tail
(indicated as an orange triangle). This selects for tetherin proteins that evade
recognition by the Nef proteins via the accumulation of amino acid changes at
the interface of molecular recognition (indicated as a brown square and blue
circle in subsequent cycles). In turn, this provides the impetus for the selection of
viral variants that restore replicative fitness by recognizing the new motif. Thus,
iterative cycles of genetic conflict continually shape genomes and functions.
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(Daugherty and Malik, 2012). A ratio of non-synonymous substitutions/nonsynonymous sites (dN) versus synonymous substitutions/synonymous sites (dS),
i.e. dN/dS, greater than 1 indicates that the sequence evolving under positive
selection. On the other hand, a dN/dS ratio of less than 1 indicates that natural
selection has conserved the ancestral state and that the sequence is evolving
under purifying selection. As expected, the majority of human genes have
evolved under purifying selection whereas a subset has evolved under positive
selection (Meyerson and Sawyer, 2011). Positively selected genes include those
involved in sensory perception, likely driven by the requirement to sense
environmental changes, food sources, or predators. Predictably, they also
include those involved in pathogen defense, including restriction factors. Notably,
APOBEC3G and TRIM5α are among the highest dN/dS ratios of human genes
(Sawyer et al., 2004; Sawyer et al., 2005; Song et al., 2005).
Positively selected residues are typically found at molecular recognition
interfaces between host and viral proteins that are involved in a long series of
genetic conflict. For example, a few amino acids in APOBEC3G that are
important for Vif antagonism are known to have evolved under positive selection
(Sawyer et al., 2004). Similarly, portions of TRIM5α that bear the signatures of
positive selection are found only in the SPRY domain, which directly binds to the
incoming retroviral capsid (Sawyer et al., 2005; Song et al., 2005). Although the
overall dN/dS ratio is quite low for tetherin, portions of its cytoplasmic tail and
transmembrane domain that are targeted by viral antagonists have evolved
under positive selection (Gupta et al., 2009a; McNatt et al., 2009). Similarly,
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SAMHD1 sequences that are determinants for Vpx sensitivity also exhibit
positive selection. Thus, each of the four classes of restriction factors exhibit
signatures of positive selection over portions of their sequence.

Restriction factors are determinants of viral host range
Positive selection causes high interspecies protein sequence variability in
restriction factors. For instance, their sequences are unusually divergent across
even primate species. Hence, the adaptations that a virus acquires in order to
antagonize restriction factor variants in one host species can come at the cost of
susceptibility to variants in another species. This diminishes the likelihood of a
virus managing to overcome the array of defenses that it confronts, when it gets
the opportunity to colonize a new host species. Thus, zoonoses that result in
successful cross-species transmissions are probably quite rare events.
Blocks to cross species transmission that are imposed by the prototypical
restriction factors, APOBEC3G and TRIM5 proteins appear particularly
formidable, perhaps because (i) these two restriction factors are especially potent
inhibitors, and (ii) they are constitutively expressed in the natural target cells of
primate lentiviruses. HIV-1 and SIV Vif proteins are universally capable of
antagonizing APOBEC3G proteins in their natural hosts, but are often impotent
when confronted with APOBEC3G proteins from other primates (Bogerd et al.,
2004; Mariani et al., 2003; Schrofelbauer et al., 2004; Virgen and Hatziioannou,
2007). Indeed, the inability of many SIV Vif proteins to induce degradation of
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human APOBEC3G might explain why many SIVs have been unable to colonize
humans (Gaddis et al., 2004). Notably, SIVCPZ Vif and SIVSMM Vif are both active
against human APOBEC3G, and both of these lineages have managed
successful zoonotic transmissions to humans (as HIV-1 and HIV-2, respectively)
(Compton and Emerman, 2013).
Although human TRIM5α is largely ineffective as an inhibitor of primate
lentiviruses, simian variants can be very potent inhibitors, and those found in
some species (e.g. African green monkeys) are capable of restricting an
impressively diverse array of retroviruses (Hatziioannou et al., 2004; Keckesova
et al., 2004; Perron et al., 2004; Yap et al., 2004). Although lentiviruses have not
evolved a novel gene specifically to antagonize TRIM5α, evasion is achieved via
the acquisition of amino acid changes in the capsid protein.
Species-specific SAMHD1 degrading activities are also evident among Vpr and
Vpx proteins and some Vpx and Vpr appear to have specialized to deal with
SAMHD1 variants that are present in the natural host species (Laguette et al.,
2012; Lim et al., 2012). However, SAMHD1 may not be a powerful barrier to
cross-species transmission, because HIV-1 apparently lacks the ability to
antagonize human SAMHD1, yet has spread globally in human populations.
Rather, the ability of a particular primate lentivirus to antagonize SAMHD1 may
determine the extent to which myeloid cell types are infected within a particular
host species.
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In contrast, tetherin poses a significant barrier to cross-species transmission of
primate lentiviruses. Vpu and Nef proteins of lentiviruses are generally only able
to antagonize tetherin from a narrow range of species. For example, most HIV-1
Vpu proteins antagonize human tetherin but are impotent against monkey
tetherin proteins (McNatt et al., 2009). Moreover, SIV Nef proteins can
antagonize tetherin proteins in their host species, but are incapable of
recognizing human tetherin (Jia et al., 2009; Zhang et al., 2009). An intriguing
series of adaptations might have been responsible for the successful colonization
of humans by HIV-1 (Sauter et al., 2009). Prior to the zoonotic transmission from
chimpanzees to humans, SIVCPZ arose through a recombination event between
two SIV lineages that are found in simian species that chimpanzees prey upon.
Remarkably, one of those SIVs employs Vpu as a tetherin antagonist while the
other employs Nef, and thus SIVCPZ became armed with two tetherin antagonists.
Adaptation of the recombinant SIVCPZ in chimpanzees resulted in the selection of
Nef as its tetherin antagonist and the loss of tetherin antagonist function by Vpu.
However, upon transmission to humans, SIVCPZ encountered a tetherin variant
that was insensitive to its Nef protein (due to the deletion of a G/D14DIWK18 motif
in the cytoplasmic tail of tetherin) and, as a consequence, had to devise an
alternative route to nullify tetherin. Thus, Vpu rapidly adapted to recover its lost
function (Sauter et al., 2009). These instances underscore the role of tetherin in
shaping lentiviral evolution.
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Evolutionary origins of restriction factors
Notwithstanding the remarkable advances in the study of restriction factors, we
still know very little about their emergence and evolutionary history. Do they arise
de novo as completely new genes, or do they emerge via fairly minor adaptations
of pre-existing cellular genes whose normal function includes the intrinsic
potential to inhibit a certain stage of the viral replication cycle? In general, three
mechanisms whereby new genes are generated include non-homologous
recombination, retrotransposition and gene duplication (Long, 2001). Exons from
different genes might form new genes by illegitimate recombination and acquire
new functions.

Retrotransposition occurs when a message RNA (mRNA) is

reverse transcribed to complementary DNA (cDNA) entirely bereft of introns, and
then inserted into the genome. Gene duplication is considered an important
mechanism for innovation of novel functions. A duplicated daughter gene might
have three possible evolutionary fates: (i) it might become a pseudogene due to
random mutations incurred via drift, (ii) it might share the functional workload of
the ancestral gene, and, (iii) because it is a redundant copy, it might be released
from functional constraints, and is thus well-suited to evolve rapidly and acquire
new functions.
In general, restriction factors are members of gene families that have undergone
dramatic expansions via gene duplication. The emergence of the APOBEC3
family of proteins, which hypermutate viral genomes, likely occurred via
sequential gene duplication events from cytidine deaminases that have important
roles in somatic hypermutation, class switch recombination and RNA editing (AID
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and APOBEC1). Because AID is found in fish, it is suspected that an ancestral
AID gene might have duplicated and diverged to produce APOBEC1 (Refsland
and Harris, 2013). Thereafter, the APOBEC3 family of proteins might have arisen
via duplications of the ancestral AID/APOBEC1 gene locus. Similarly, one could
envisage a scenario wherein SAMHD1 arose via gene duplication of one of the
metalloenzyme with phosphohydrolytic activity. In this instance, the metabolic
function of SAMHD1 (i.e. regulation of cellular deoxynucleotide pools) could have
been conveniently harnessed by cells to inhibit the reverse transcription step in
the retroviral life cycle. It is unclear exactly how TRIM5 emerged, but it likely
evolved by duplication and divergence of one of the members of the ~100 TRIM
proteins. Although most of these do not possess intrinsic antiretroviral activity,
TRIM1 and TRIM34 exhibit weak antiretroviral activity when overexpressed
(Zhang et al., 2006). Remarkably, independent retrotransposition events in Owl
monkey and macaque TRIM5 genes have resulted in the replacement of the Cterminal SPRY domain with a complementary DNA sequence encoding
cyclophilin A. The antiviral activity of these novel “TrimCyp” proteins against HIV1 is dependent on their ability to recognize and bind the capsid protein (Sayah et
al., 2004; Virgen et al., 2008). Interestingly, humans only contain a single TRIM5
copy, whereas the genomes of cows, rats, and mice contain tandemly clustered
arrays of TRIM5 genes, although not all variants have been reported to possess
antiviral activity (Fletcher and Towers, 2013). It is difficult to imagine how such
TRIM5 arrays, and the few dozen TRIM proteins might have evolved without
gene duplication.
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One intriguing question about restriction factors is whether they arose purely as
antiviral genes. Put another way, do they perform cellular functions that are
unrelated to their antiviral activity? A few pieces of evidence are consistent with
the notion that restriction factors might have evolved primarily to inhibit the
replication of viruses. First, restriction factors are either constitutively active
(APOBEC3G and TRIM5) or are strongly upregulated by interferons (tetherin)
(Malim and Bieniasz, 2012). Second, each restriction factor typically inhibits the
replication of viruses by either targeting a specific component of the virion
(genome, capsid, and envelope) or by interfering with a process that is critical to
the viral life cycle (reverse transcription, nuclear import, assembly) (Blanco-Melo
et al., 2012). Third, viruses evolve novel countermeasures to antagonize
restriction factors in their host species, although this renders them susceptible to
variants in other species. Fourth, restriction factors have evolved under positive
selection and harbor a high number of polymorphisms even within species
(Johnson, 2013). Each variant was probably shaped independently by
antagonistic interactions with past viruses. Fifth, the genes encoding restriction
factors are dispensable for host viability. For instance, mice harboring deleterious
lesions in APOBEC3 and tetherin have no obvious developmental abnormalities.
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Tetherin- a restriction factor against enveloped viruses
History and discovery of tetherin
Investigations that aimed to elucidate the role of the HIV-1 protein Vpu routinely
observed that it was required, in a cell type-specific manner, for the efficient
release of progeny virions from the surfaces of infected CD4+ T cells and
macrophages (Gottlinger et al., 1993; Klimkait et al., 1990). Cell types such as
HeLa, Jurkat T and Hep-2 were observed to be “non-permissive” for the
replication of Vpu-deficient HIV-1 whilst HOS, 293T, HT1080, COS and CV-1
cells were deemed “permissive” (Gottlinger et al., 1993; Neil et al., 2006; Neil et
al., 2007). Fusion experiments between the permissive COS cells and nonpermissive HeLa cells generated heterokaryons that also did not support the
release of Vpu-deficient HIV-1 virions (Varthakavi et al., 2003). As explained
earlier, such a result hinted at the presence of a dominant restriction factor in
non-permissive cells that was absent in permissive cells but retained activity in
heterokaryons (Varthakavi et al., 2003). Interestingly, the expression of Vpu in
trans efficiently released virions from these heterokaryons, indicating that it
probably reversed the inhibitory effect by antagonizing the putative restriction
factor (Varthakavi et al., 2003). Strikingly, the requirement for Vpu was induced in
interferon-α (IFN-α) treated HT1080 and 293T cells, suggesting that perhaps this
restriction factor was mobilized as part of a global antiviral response, even in
permissive cells (Neil et al., 2006; Neil et al., 2007). These studies laid the
foundation for the identification of tetherin (also known as BST-2, CD317, or
HM1.24) as a HIV-1 restriction factor that is the cellular target of Vpu. A list of
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candidate genes were pruned by comparing gene expression profiles between (i)
HT1080, 293T and Jurkat T cells that were either untreated or treated with IFN-α,
and (ii) non-permissive HeLa cells and permissive HOS cells (Neil et al., 2008)
Tetherin emerged as a leading candidate because (i) it was a membrane protein,
(ii) it was strongly induced by IFN-α treatment in HT1080, 293T and Jurkat T
cells cells, and (iii) it was expressed in HeLa cells, but was absent in HOS cells
(Neil et al., 2008).

Structural features of tetherin
Tetherin is a type II membrane protein whose ectopic expression causes the
physical entrapment of nascent mature enveloped virions at the cell surface
(Evans et al., 2010; Hammonds et al., 2012; Neil et al., 2008; Swiecki et al.,
2012; Van Damme et al., 2008). Structurally, it comprises of a short N-terminal
cytosolic tail, a single pass transmembrane helix, an extracellular domain that is
predominantly an alpha helical coiled-coil (Hinz et al., 2010; Schubert et al.,
2010;

Swiecki

et

al.,

2011;

Yang

et

al.,

2010),

and

a

C-terminal

glycosylphosphatidylinositol (GPI) moiety that is a second membrane anchor
(Andrew et al., 2009; Kupzig et al., 2003; Ohtomo et al., 1999) (Figure 1.6).
Three invariant cysteine residues in its ectodomain (C53, C63, and C91) stabilize
parallel homodimer formation via disulphide bridges (Figure 1.6). Also, tetherin is
glycosylated at two asparagine residues, which is responsible for its proper
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Figure 1.6. Structural features of tetherin. The tetherin molecule comprises of
a short N-terminal cytosolic tail, a single pass transmembrane helix, an
extracellular domain that is predominantly coiled-coil. It is also modified at its Cterminus with a glycosylphosphatidylinositol (GPI) moiety. Three extracellular
cysteine residues drive parallel homodimer formation via disulphide bridges
(indicated as grey lines).
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folding and anterograde transport to the plasma membrane (Perez-Caballero et
al., 2009).
Crystals structures have revealed that the ectodomain is essentially a ~170Å rodlike parallel homodimer, with its two N-termini ends splayed apart (Hinz et al.,
2010; Schubert et al., 2010; Swiecki et al., 2011; Yang et al., 2010). The coiledcoil domain is surprisingly quite flexible and is capable of rotating around two
pivotal residues. Up to ∼25° rotation is permitted at A88 and up to ∼18° rotation
is permitted at G109 due to packing defects of the coiled-coil domain (Yang et

al., 2010). Perhaps the conformational flexibility of the coiled-coil around these
two hinge points preserves dimeric integrity when dramatic changes in
membrane curvature occur during virion assembly (Swiecki et al., 2011; Yang et
al., 2010).
Under reducing conditions, the tetherin ectodomain undergoes tetramerization
through a 4-helix bundle interaction (Schubert et al., 2010; Yang et al., 2010).
Although its biological relevance is yet to be determined, two lines of evidence
suggest that the formation of tetramers is not essential for the antiviral activity of
tetherin. First, C53/C53 and C63/C63 disulphide bridges cannot form in the
tetramer because they are far too spatially separated (Yang et al., 2010); yet, all
three cysteine residues form disulphide bridges in tetherin dimers in cells
(Andrew et al., 2009; Perez-Caballero et al., 2009) and are essential for optimal
virion retention (Perez-Caballero et al., 2009). Second, a tetherin variant which
targets amino acids that are critical for tetramer formation, is only modestly
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impaired in its function, confirming that the tetrameric form of tetherin is
dispensable for tethering (Yang et al., 2010).

Cellular localization and distribution of tetherin in tissues
Tetherin was originally cloned from a bone marrow stromal cell line (hence the
name bone marrow stromal cell antigen 2, or BST-2) derived from a rheumatoid
arthritis patient that could facilitate stromal cell-dependent growth of a pre-B-cell
line (Ishikawa et al., 1995). It has also been described as a tumor antigen that is
expressed on the surface of human multiple myeloma cells (Ohtomo et al.,
1999), and on plasmacytoid dendritic cells (Blasius et al., 2006). An early survey
of tetherin expression indicated that its transcript is well-expressed in liver, lung,
placenta, and heart (Ishikawa et al., 1995). However, a comprehensive
evaluation of tetherin expression in vivo showed that it is expressed in a wider
range of tissues that included spleen, gallbladder, pancreas, kidney, liver, the GI
tract and blood vessels (Erikson et al., 2011).
Analyses of an ~2-kb DNA fragment upstream to the transcription start site (TSS)
of the tetherin gene have revealed the presence of cis-regulatory elements such
as interferon stimulated response elements (ISREs) and γ-activated site (GAS),
as well as several potential binding sites interspersed in the region, for the signal
transducer and activator of transcription (STAT), interferon regulatory factors
(IRFs), NF-κB and NF-AT (Bego et al., 2012; Ohtomo et al., 1999). Notably, a
cluster of sequences proximal to the TSS (~150 bp upstream), is required for
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induction by IFN-α (Bego et al., 2012). This “interferon response cluster”
comprises of an ISRE, a GAS as well as binding sites for IRFs. Interestingly,
tetherin expression can also be induced in the absence of type I IFN signaling by
IRFs 1, 3, and 7, suggesting that it might be directly activated by viral infection,
independently of IFN signaling (Bego et al., 2012). This view is reinforced by the
stimulation of tetherin expression upon treatment with agonists of TLR3 and
TLR8 and prior to any detectable interferon signaling (Bego et al., 2012).
In cells, tetherin resides at the cell surface and is recycled back to the early
endosomes and trans-Golgi network (TGN) via the endocytic pathway (Rollason
et al., 2007). Interestingly, its GPI anchor is believed to facilitate its free diffusion
to cholesterol- and sphingolipid-rich microdomains at the plasma membrane
(Kupzig et al., 2003). It is thought that tetherin molecules oriented such that their
GPI anchors are within microdomains might serve as boundaries of such
structures (Billcliff et al., 2013). A role for integral membrane proteins in the
stabilization of microdomains by mediating interactions with the underlying actin
cytoskeleton has been hypothesized by Sheetz (Sheetz, 1983). Indeed, the
cytoplasmic tail of tetherin has been shown to interact with the actin cytoskeleton
via RICH2 (Rollason et al., 2009), but this interaction is dispensable for antiviral
activity. Thus, the ability of tetherin to trap virions might simply be a consequence
of its preferential localization to cholesterol-rich microdomains, the site of HIV-1
assembly (Nguyen and Hildreth, 2000). A similar argument can be invoked to
explain why tetherin specifically traps virions and not exosomes. The latter are
vesicles that are released from the cell when multivesicular bodies fuse with the
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plasma membrane (Denzer et al., 2000; Raposo et al., 1996; Thery et al., 2002).
Because they might bud non-specifically, rather than from cholesterol-rich
microdomains, they probably do not encounter tetherin molecules during
budding.

Mechanism of antiviral activity of tetherin
Tetherin inhibits the release of nascent enveloped virions by physically
crosslinking them to the plasma membrane, but the molecular mechanisms that
underpin the process of virion tethering have been difficult to determine.
Accumulating evidence seems to indicate that tetherin acts directly and
autonomously to trap virions. First, trapped virions can be liberated from the cell
surface by treatment with the protease subtilisin A, indicating that the tether itself
is composed of protein (Neil et al., 2007). In such experiments, tetherin
fragments can be found in subtilisin-liberated virions (Perez-Caballero et al.,
2009). Second, both membrane anchors are essential for antiviral activity, and
inactive tetherin proteins that lack either of the two membrane anchors, are
efficiently incorporated into virions (Perez-Caballero et al., 2009). Third,
fluorescent and electron microscopic analyses demonstrate that tetherin is
localized at sites of virion entrapment (Fitzpatrick et al., 2010; Hammonds et al.,
2010; Lehmann et al., 2011; Perez-Caballero et al., 2009). Fourth, an artificial
tetherin protein assembled from heterologous protein domains that have similar
configuration but no primary sequence homology to tetherin, recapitulates
tetherin function (Perez-Caballero et al., 2009). Taken together, these findings
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suggest that (i) the biological activity of tetherin can be ascribed to its overall
configuration rather than its primary sequence and (ii) tetherin does not require
specific cofactors or the recognition of specific viral components to cause virion
entrapment. These findings are difficult to reconcile with complex models in
which tetherin might act as a virion sensor to induce other factors that have
tethering activity. Rather, they are more easily explained by the idea that tetherin
acts autonomously and directly to trap virions, simply as a consequence of being
incorporated into the lipid envelope of virions as they bud through cell
membranes. Consistent with these arguments, tetherin exhibits antiviral activity
against a broad spectrum of enveloped virions whose proteins have essentially
no sequence homology (Dietrich et al., 2011; Jouvenet et al., 2009a; Mansouri et
al., 2009; Radoshitzky et al., 2010; Sakuma et al., 2009; Watanabe et al., 2011;
Weidner et al., 2010; Yondola et al., 2011).
Because a protected, β-mercaptoethanol-sensitive, dimeric amino-terminal
tetherin fragment can be recovered from virions that have been liberated by
protease treatment, it appears that at least some trapped virions are infiltrated by
both N-termini of a parallel tetherin homodimer (Perez-Caballero et al., 2009).
Moreover, a tetherin variant that lacks a GPI anchor preferentially localizes to
sites of viral budding, suggesting that the tetherin N-terminus provides the
dominant driving force for infiltration into budding virions (Perez-Caballero et al.,
2009). These results have also been supported by other studies involving superresolution microscopy (Lehmann et al., 2011). Nevertheless, it remains a
tantalizing challenge to establish unequivocally that tetherin is directly
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responsible in trapping virions, and to determine the precise configurations that
might be adopted by tetherin homodimers as they engage in virion entrapment.
Upon virion entrapment, the tetherin-virus complexes accumulate in early and
late endosomes. The internalization of virions is dependent on endocytosis,
because dominant-negative forms of dynamin (K44A) and Rab5a (S34N) that
inhibit this process, abolish the intracellular accumulation of virions (Neil et al.,
2006). Virion uptake might also be facilitated by interactions with BCA2, a Rab7interacting protein with E3 ubiquitin ligase activity (Miyakawa et al., 2009).
Ultimately, virions infiltrated by tetherin are either sequestered or targeted for
degradation in lysosomes (Neil et al., 2006).

Antagonism of tetherin by viral proteins
One argument in favor of the notion that tetherin acts quite nonspecifically to trap
enveloped virions arises from the mechanisms that viruses have evolved to
evade the action of tetherin. Rather than acquiring viral protein sequence
changes that might enable escape from interaction with tetherin, viruses have
instead adapted novel genes to gain interaction with, and thereby antagonize,
tetherin. For instance, HIV-1 has evolved an accessory protein Vpu to overcome
the antiviral effects of tetherin (Neil et al., 2008). Vpu is a type I integral
membrane protein that comprises an N-terminal transmembrane domain followed
by a cytoplasmic tail that consists of two α-helices separated by an acidic flexible
loop that contains a conserved casein kinase II phosphorylation motif
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(S/T52xxD/ES56) (Cohen et al., 1988; Strebel et al., 1988). Domain replacement
experiments have shown that the transmembrane domain of tetherin carries
critical determinants of sensitivity or resistance to Vpu (McNatt et al., 2009).
Strikingly, two mutations (∆GI/T45I) in the transmembrane domain that mimic
tetherin proteins in rhesus macaques and African green monkeys, render human
tetherin completely insensitive to Vpu (McNatt et al., 2009). Recent crosslinking
studies have unequivocally demonstrated that Vpu and tetherin interact directly
via their transmembrane domains (McNatt et al., 2013).
Phosphorylation of the two serine residues in the S/T52xxD/ES56 motif (Schubert
et al., 1994) governs the recruitment of the adaptor protein β-TrCP and its
associated Skp1/Cullin/F-Box (SCF) E3 ubiquitin ligase complex (Margottin et al.,
1998). Vpu physically associates with tetherin via their transmembrane domains
(Dube et al., 2009; Iwabu et al., 2009; Kobayashi et al., 2011; McNatt et al.,
2013; McNatt et al., 2009; Vigan and Neil, 2010), and employs surface
downregulation (Dube et al., 2009; Hauser et al., 2010; Schindler et al., 2010;
Schmidt et al., 2011; Skasko et al., 2011; Van Damme et al., 2008) and
degradation (Douglas et al., 2009; Goffinet et al., 2009; Iwabu et al., 2009;
Mangeat et al., 2009; Mitchell et al., 2009) to antagonize tetherin.
Notably, a mutant of Vpu that harbors serine-to-alanine mutations is impaired at
carrying out both activities, but still retains a modest ability to antagonize tetherin
at the cell surface (Douglas et al., 2009; Iwabu et al., 2009; Schindler et al.,
2010). It does so by merely binding and displacing tetherin from sites of viral
assembly (McNatt et al., 2013). In this regard, an E63xxxLV68 motif in the Vpu
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cytoplasmic tail is essential for downregulation and degradation of tetherin, as
well as its displacement from sites of virion assembly (Kueck and Neil, 2012;
McNatt et al., 2013).
A number of reports have demonstrated that Vpu alters the anterograde transport
of de novo synthesized tetherin molecules or those that are recycling between
the trans-Golgi network (TGN) and the plasma membrane (Dube et al., 2010;
Dube et al., 2009; Kueck and Neil, 2012; Neil, 2013). By stationing itself in the
TGN, Vpu intercepts tetherin molecules en route to the plasma membrane and
diverts them to the endosomal compartments via clathrin-dependent transport
(Lau et al., 2011). Ubiquitination of tetherin at multiple residues in its cytoplasmic
tail, and in particular a S3TS5 motif, targets it for degradation in late endosomes
(Skasko et al., 2011). Vpu-dependent recruitment of the ESCRT-0 subunit HRS,
which binds ubiquitinated molecules, enhances the sorting of tetherin-Vpu
complexes into the multivesicular bodies of late endosomes (Janvier et al.,
2011). Thus, this redirection of Vpu-tetherin complexes to the late endosomes
prevents them from recycling to the cell surface, and most importantly, ensures
that tetherin can no longer be salvaged for the purpose of virion tethering.
Most viruses that do not encode Vpu exploit their Nef proteins to antagonize
tetherin (Jia et al., 2009; Lim et al., 2010; Sauter et al., 2009; Zhang et al., 2011;
Zhang et al., 2009). Nef is a multifunctional viral protein that regulates the levels
of a variety of cell surface proteins such as CD4 (Kirchhoff et al., 2008). The
mechanism of antagonism involves a direct physical interaction between Nef and
tetherin (Serra-Moreno et al., 2013), and as mentioned earlier, the binding
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determinants map to a G/D14DIWK18 motif that is present in the cytoplasmic tails
of simian tetherin proteins (Jia et al., 2009; Zhang et al., 2009). Nef induces the
internalization of tetherin by binding to AP-2 clathrin adaptor complexes (Zhang
et al., 2011). Remarkably, human tetherin lacks this motif, which imposed a
strong selection pressure on HIV-1 and HIV-2 to adapt their Vpu and Env genes
for tetherin antagonism, after zoonoses from chimpanzees and sooty mangabeys
respectively.
Other viruses employ their Env proteins to antagonize tetherin. The HIV-2 Env
protein has evolved to antagonize tetherin by promoting its internalization and
accumulation in the TGN (Gupta et al., 2009b; Hauser et al., 2010; Le Tortorec
and Neil, 2009). The residues that are specifically involved are not well defined
and are situated in the ectodomains of both proteins. Antagonism is achieved by
clathrin-mediated endocytosis, via a conserved endocytic motif in the cytoplasmic
tails of gp41 proteins. Additionally, the SIVMAC Env (Serra-Moreno et al., 2011)
and Ebola glycoprotein (Kaletsky et al., 2009; Lopez et al., 2010) proteins have
adapted to antagonize tetherin proteins in their hosts by targeting different
portions of the cytoplasmic tail or the ectodomain respectively.
The diverse ways in which viruses have adapted to antagonize tetherin
emphasize the incredible plasticity of their genomes and their ability to innovate
in response to selective pressures. It is difficult to speculate as to why three
different viral proteins have been deployed to antagonize tetherin. One possible
reason could be that tetherin is the only restriction factor that resides in three
different compartments, i.e. in the cytosol, plasma membrane and in the
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extracellular region, and is thus susceptible to the viral proteins that also localize
to these compartments. Second, during a zoonotic transmission, it is possible
that a virus might confront a tetherin protein that cannot be easily overcome by
its present antagonist. In such an instance, it might be less challenging for any of
the other two accessory genes to evolve or regain this function. Thus, it is clear
that tetherin has a role in shaping viral evolution.

Role of tetherin in various modes of transmission
It is believed that viruses disseminate within hosts via two distinct modes of
transmission between cells either by freely diffusing particles that have been
released into the cell-free supernatant (i.e. cell-free transmission), or via direct
contact

between

cells

(i.e.

cell-to-cell

transmission).

Clearly,

cell-free

transmission is unencumbered by the need of intimate cell-to-cell contact and is
thus useful in establishing long-range infections within and between hosts.
However, in certain scenarios, cell-free transmission might be rather inefficient
for the spreading of virus. For instance, virions released into the extracellular
milieu might be labile or might be subjected to the action of neutralizing
antibodies. In such instances, viral spread to neighboring cells via cell-to-cell
transmission could be imagined to be far more efficient.
Cell-to-cell transmission involves the concerted action of adhesion molecules,
cytoskeletal rearrangements, and polarization of receptor molecules to promote
the transfer of virions across a “virological synapse” (VS) (Chen et al., 2007; Jolly
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et al., 2004; Sattentau, 2008). These structures are formed due to interactions
between the viral envelope on the infected (donor) cell and the receptors on the
target (acceptor) cell, and are very reminiscent of immunological synapses that
are bridged by interactions between ICAM-1 and LFA-1 (Jolly et al., 2004; Jolly et
al., 2007; Rudnicka et al., 2009). Viral particles can be transferred across long
filopodial membrane bridges that connect donor and target cells (Helenius et al.,
1980; Hubner et al., 2009; Sherer et al., 2007; Smith and Helenius, 2004).
However, unlike neural and immunological synapses, the existence and
biological relevance of virological synapses has not been convincingly
demonstrated in vivo. In fact, an argument that is oftentimes made is that cell-tocell transmission is actually cell-free transmission over extremely short distances,
and that the greater efficiency of the latter mode might reflect the high
multiplicities of infection that are achieved due to the increased availability of
released virions into a confined area.
Thus far, the majority of investigations on tetherin have focused on its role in
inhibiting cell-free transmission, but a few studies have attempted to delineate its
impact on cell-to-cell transmission. It has been reported that when HIV-1 is
selected to disseminate rapidly in culture, i.e. in the time frame wherein cell-tocell transmission would be more efficient, lesions in vpu are common
(Gummuluru et al., 2000). It should be noted, however, that cells were frequently
washed during this study, and such an artificial system is not physiologically
relevant. After the discovery of tetherin, a number of studies examined its role in
modulating cell-to-cell transmission and came to opposing conclusions. Two of
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these studies suggested that tetherin inhibits cell-to-cell transmission (Casartelli
et al., 2010; Kuhl et al., 2010), while the third indicated that tetherin plays a
supporting role (Jolly et al., 2010). These discrepancies could be attributed
simply to the different surface expression levels of tetherin in the cell lines used
in these investigations. In low tetherin-expressing Jurkat T cells, it is possible that
a small amount of virions are released and can productively infect bystander cells
(Jolly et al., 2010). On the other hand, in transiently transfected 293T cells,
wherein tetherin is expressed at amounts far greater than endogenous levels,
hardly any virions are released to infect neighboring cells (Casartelli et al., 2010).
Thus, it is difficult to conclude whether tetherin aids or inhibits cell-to-cell
transmission, due to the conflicting nature of these studies. Furthermore, the
relative importance of cell-to-cell transmission is yet to be firmly established in
vivo.
Various approaches such as the transwell coculture system and agar overlay
assays might be employed to assess the contribution of tetherin to cell-to-cell
transmission. In the transwell coculture system, viral spread would be expected
to occur via cell-free rather than cell-to-cell transmission. In contrast, viral spread
would be expected to occur predominantly via cell-to-cell rather than cell-free
transmission in the agar overlay assays. Thus, the role for tetherin could be
analyzed by comparing the ability of Vpu-deficient virus to establish spreading
infections in tetherin-deficient versus tetherin-expressing cells. In the transwell
coculture system, a Vpu-deficient virus would be expected to establish a
spreading infection more efficiently in tetherin-deficient cells compared to
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tetherin-expressing cells. This is intuitive, given that transmission occurs solely
via the cell-free mode. In contrast, if tetherin aids cell-to-cell transmission, then
spreading infections would be more efficient in tetherin-expressing cells rather
than the tetherin-deficient cells, and this could be analyzed using the agar
overlay assays.

The biological relevance of tetherin in vivo
Accruing evidence supports an important role for tetherin in limiting viral burden
and dissemination in vivo. First, the ability of the Vpu proteins of the HIV-1 group
M strains to efficiently antagonize human tetherin as well as to degrade CD4
seems to have contributed to the success of this lineage in colonizing human
populations as compared to the HIV-1 group N, O and P strains, whose Vpu
proteins are either severely impaired or impotent against tetherin (Sauter et al.,
2009). Second, an inspection of natural Vpu alleles found in infected individuals
at different stages of disease found that although there was considerable T-cell
driven variation in the Vpu proteins, only a minority of these alleles were
defective for antagonism of tetherin (Pickering et al., 2014). The strict
maintenance of this function at all stages of infection indicates a selection
pressure imposed by tetherin. Third, a tetherin allele with an insertion
polymorphism in its promoter that results in lower surface levels of protein
expression correlates with rapid disease progression in HIV-1 patients (Laplana
et al., 2013). Fourth, a Nef-deficient of SIV that is incapable of tetherin
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antagonism reverts to a pathogenic phenotype after serial passages in rhesus
macaques (Serra-Moreno et al., 2011). Importantly, the determinants of
resistance to rhesus tetherin map to the cytoplasmic tail of gp41. Antagonism of
rhesus tetherin is achieved via internalization and sequestration, in a manner
reminiscent of how human tetherin is antagonized by HIV-2 Env. Fifth, two
mutations confer HIV-1 Nef with the ability to antagonize chimpanzee tetherin
after a single passage in chimpanzees (Gotz et al., 2012).
Investigations in mice have also documented a role for tetherin in vivo. In one
study with Tetherin deficient mice, it was shown that Tetherin inhibits Moloney
MLV and a pathogenic MLV known as LP-BM5 in vivo (Liberatore and Bieniasz,
2011). Because Moloney MLV replicates without inducing a type I IFN response,
stimulation with poly (I:C) was required to induce tetherin expression and
attenuate viral replication in WT mice compared to tetherin-deficient littermates.
In contrast, LP-BM5 induces immune activation, polyclonal B-cell proliferation,
and impaired immune responses very reminiscent of HIV/AIDS. Importantly, it
induces type I IFN in infected tissues ~8 weeks after replication and this led to
the attenuation of LP-BM5 plasma viremia and pathogenesis in wild type mice as
compared to the tetherin-deficient mice.
In another study that correlated genotype, phenotype and virus replication in
vivo, a single nucleotide polymorphism (SNP) was identified in the tetherin gene
of NZW mice wherein the start codon was mutated, resulting in the expression of
a shorter isoform of tetherin (Barrett et al., 2012). Because its cytosolic tail is
truncated and lacks the YxY endocytosis motif, the variant is retained at higher
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levels at the surfaces of splenocytes, dendritic cells, B cells and erythroblasts,
leading to diminished levels of infectious plasma viremia and viral loads. Thus,
tetherin can control virus replication in vivo.
More recent work using a humanized mouse model of acute R5-tropic HIV-1
infection provides clear evidence that tetherin antagonism by Vpu is critical for
viral dissemination (Dave et al., 2013). Mice infected with a Vpu-deficient HIV-1
showed attenuated viral loads and lower numbers of infected T cells in
splenocytes. It is interesting to note that mice infected with HIV-1 Vpu carrying
mutations in the β-TrCP binding domain had intermediate viral loads as
compared to mice that were infected with WT or Vpu-deficient viruses, supporting
the view that down regulation of tetherin from the cell surface is only one of the
myriad ways that Vpu counteracts tetherin.

Auxiliary functions of tetherin
The primary function of tetherin is to physically inhibit the release of enveloped
virions from the cell surface, but it might also have auxiliary functions that
augment its antiviral activity. In fact, prior to its identification as an antiretroviral
restriction factor, tetherin was identified as an activator of NF-κB in a wholegenome cDNA screen (Matsuda et al., 2003). Thus, analogous to the Toll-like
receptors (TLRs) that act as pattern recognition molecules (Iwasaki, 2012;
Medzhitov and Janeway, 2000), tetherin might initiate proinflammatory signaling
cascades upon directly engaging the virus. In support of this view, three studies
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have recently revealed a signaling function of tetherin that is genetically
separable from, and downstream to, its antiviral activity (Cocka and Bates, 2012;
Galao et al., 2012; Tokarev et al., 2012).
The accumulation of tetherin-virus complexes in late endosomal compartments
might be expected to increase the visibility of virion components to TLRs in
intracellular compartments and activate NF-κB signaling via the IRF pathway.
However, the emerging view is that tetherin triggers the expression of
proinflammatory cytokines upon trapping viral particles at the cell surface (Galao
et al., 2012). Mutations in its N-terminal YDY endocytosis motif and a proximal
CRV motif abolishes NF-κB signaling (Galao et al., 2012; Tokarev et al., 2012).
Accumulation of trapped virions at the cell surface leads to the YDYCRVdependent recruitment of the E3 ubiquitin ligase TRAF2/6 and the E2 ubiquitin
conjugating enzyme Ubc13, which activate the TAK1 complex (Galao et al.,
2012; Tokarev et al., 2012). This, in turn, induces phosphorylation and
proteasomal degradation of IκB via IKK that results in the activation of NF-κB
signaling.
In another study, it was demonstrated that two isoforms of tetherin, derived by
translation initiation from different methionine residues, are produced in both
cultured human cell lines and primary cells (Cocka and Bates, 2012). Notably,
the shorter isoform lacks the N-terminal YDYCRV motif, and fails to induce NFκB activation. It is also more resistant to antagonism by Vpu and is thus more
effective at trapping virions. However, the physiologic relevance of the shorter
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isoform of tetherin in vivo, if any, is unclear because Vpu is a potent tetherin
antagonist even in primary cells.
Thus, the attributes of tetherin that endow it with the ability to act as a virion
sensor remain to be determined. It has been suggested that tetherin facilitates
the organization of lipid rafts or microdomains that might act as scaffolds for NFκB signaling (Billcliff et al., 2013). Indeed, the mere clustering of tetherin
molecules is sufficient to trigger NF-κB signaling, albeit not as potently (Galao et
al., 2012).
Virion retention at the cell surface might inadvertently have other consequences,
i.e. it could potentiate antibody-dependent cellular cytotoxicity (ADCC), a humoral
immune response mediated by natural killer cells (Ohtomo et al., 1999). The
clustering of tetherin molecules might increase the visibility of viral antigens,
leading to their opsonization and engagement by effector cells. ADCC ultimately
results in the killing of HIV-1 infected cells via cytolytic granules. In support of this
idea, tetherin-expressing cells infected with Vpu-deficient HIV-1 tend to be more
susceptible to ADCC in vitro (David Evans, unpublished results). Thus, the
antagonism of tetherin might be useful in shielding infected cells from ADCC.
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Chapter II Materials and methods
Plasmid construction
All tetherin and PV1 proteins were transiently expressed using pCR3.1
(Invitrogen) based plasmids or stably expressed using pLHCX (Clontech) based
retroviral vectors. A human tetherin protein internally tagged with an HA epitope
at amino acid 155 and, expressed using pCR3.1 or LHCX vectors, has been
described previously (Neil et al., 2008). Eight copies of a peptide linker
sequence, each comprising the amino acid sequence GGGGS, were inserted
immediately C-terminal to the HA tag, to generate the C8 modified tetherin
protein (Figure 1D). Similarly, five GGGGS linker units were inserted immediately
C-terminal to the tetherin transmembrane domain at amino acid position 50, to
generate the N5 modified tetherin protein. Because the BamHI recognition site
(GGATCC) encodes a glycine and serine, we incorporated its sequence into the
fourth and third linker units for the C8 and N5 proteins respectively. We then
used these BamHI sites for the subsequent insertion of a Factor Xa cleavage site
(IEGR) to generate the C8Fac and N5Fac proteins (Figure 1D). Thereafter the
Flag N5Fac protein was generated by inserting three copies of a FLAG epitope
tag at the N-terminus of the N5Fac protein (Figure 1D).
The protein standard used for quantitative western blotting was generated by
appending the C-terminus of HIV-1 p24 CA protein with three FLAG epitope tags
and an HA epitope tag. Specifically, the p24 CA coding sequence was amplified
from the proviral plasmid pNL4-3 using oligonucleotides that encoded the epitope
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tags, and inserted as an EcoRI-NotI fragment into the multiple-cloning site of
pCRV-1, a previously described hybrid expression vector that is derived from
pCR3.1 and from a highly modified HIV-1 provirus (V1B).
All mutagenesis was accomplished by using overlap-extension PCR. A Vpudeficient version of pCRV-1 was generated by substituting the start codon of the
Vpu gene with a BamHI site. The chimeric Gag protein ZWT-p6 construct was a
kind gift from Heinrich Göttlinger (University of Massachusetts Medical School,
MA). The ZWT-∆p6 construct was generated by using PCR primers directed
against the corresponding sequence. The three Gag constructs: ZWT-p6, its p6ZWT-∆p6 and NL4-3 Gag were amplified and inserted as EcoRI-NotI fragments
into pCRV-1 ∆Vpu.
The panel of cysteine crosslinkable mutants (E51C, A52C, R54C, D55C, G56C,
R58C, A59C, M61C, E62C, Q142C, V143C, S145C, V146C, R147C, A149C,
D150C, K152C, Y153C and Y154C) was generated by using PCR primers
directed to the corresponding sequences in the C8Fac protein.
To generate the chimeric tetherin proteins (such as Tropo), an intermediate
construct was created by introducing NheI sites at codons 100 and 154. The
coiled-coil sequences from tropomyosin, golgin-84, CASP, golgin-97, TATA
modulatory factor 1, and early endosome antigen 1 were amplified from
complementary DNAs (cDNAs) prepared from 293T and THP-1 cells and
inserted as SpeI-NheI fragments into the previous construct. The reverse primers
were also used to introduce a HA tag C-terminal to the coiled-coils. The
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glycosylation-deficient coiled-coil constructs were generated by first identifying
the asparagine residues that are predicted to undergo glycosylation (NetNGlyc
1.0 Server, Technical University of Denmark) and mutating them to serine using
primers directed against the corresponding sequences.
The panel of mutants in which the tropomyosin coiled-coil is inserted into linker
sequences was generated by amplifying the tropomyosin coiled-coil and inserting
it as a BamHI-BamHI fragment into the third, fourth, fifth and sixth linkers in the
C8Fac protein.
The Tasmanian devil tetherin gene sequence was retrieved from Ensembl
(Release 71, Gene ID: ENSSHAG00000002838). The artificial tetherin protein,
comprising of the N-terminal cytosolic tail, transmembrane domain and part of
the extracellular region of the transferrin receptor, followed by the extracellular
coiled coil domain of the dystrophia myotonica protein kinase protein, a HA
epitope tag and the GPI anchor addition motif of the urokinase plasminogen
activator receptor, has also been described previously (Perez-Caballero et al.,
2009).
The human PV1 and the Tasmanian devil tetherin genes were constructed using
PCR-based methods (Lee and Bieniasz, 2007; Soll et al., 2010). Overlapping
60mer oligonucleotides were designed using the Genedesign online software
from

Johns

Hopkins

University

(http://slam.bs.jhmi.edu/gd).

The

target

oligonucleotide length and overlap melting temperature was set to 60 nucleotides
and 56°C, respectively. XhoI and NotI sites were added to the first and last
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oligonucleotides respectively for cloning into the pCR3.1 vector. For each gene
construction, two sequential polymerase chain reactions were carried out. The
first contained a mixture of the overlapping oligonucleotides prepared by
combining 1µL of each 100µM stock solution and then diluting ten-fold. A 50µL
PCR reaction contained 3µL of the diluted oligonucleotide mixture and gene
synthesis was carried out for 20 cycles using Phinzymes Phusion (1 min. 98°C, 1
min. 50°C, and 2 min. 72°C). The second PCR contained 2µL of crude product
from the first in a 50µL reaction with 200nM external primers. Amplification
proceeded for 25 cycles (1 min. 98°C, 1 min. 55°C, and 2 min. 72°C) and the
resulting product was gel-purified using the Qiagen gel extraction kit and cloned
into pCR3.1 using XhoI and NotI enzymes.
The PV1-GPI construct was generated by using a reverse primer that encoded
the tetherin GPI anchor sequence (amino acids 160 to 180) and a NotI site. The
DelCT variant (PV1-DelCT-GPI), which lacks the N-terminal 23 amino acids, was
generated by using a PCR primer directed to the corresponding sequence.
Sequence-validated cDNA clones (Thermo Scientific) for human CD72
(Accession no. BC030227) and mouse CLEC1A (Accession no. BC052840) were
amplified and inserted as XhoI-NotI fragments into pCR3.1. The rest of the panel
of modified PV1-like proteins was generated as above, by using PCR primers to
introduce HA-tags, tetherin GPI anchors and to truncate the N-termini.
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Cell culture
Human embryonic kidney (HEK) 293T cells and HeLa-TZM cells expressing
CD4/CCR5 and a LacZ reporter gene under control of the HIV-1 LTR (Platt et al.,
1998; Wei et al., 2002) were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FBS and gentamycin (2µg/ml, Gibco).
HEK293T cells were transduced using pLHCX based retroviral vectors
expressing genes of interest and selected with hygromycin (50 µg/ml,
MediaTech, Inc.) to generate cell lines expressing either the empty vector or
epitope-tagged WT or modified tetherin proteins.

Flow Cytometry
The 293T cells stably expressing the modified tetherin proteins and HeLa cells
were harvested in PBS plus 5mM EDTA, washed in FACS buffer (PBS plus 2%
BSA), and stained with PE anti-human CD317 (tetherin) antibody (Biolegend).
Dead cells were excluded by DAPI staining. All data were acquired on an LSR II
flow cytometer (Becton Dickinson), and data were analyzed with FlowJo software
(Tree Star).

Virus production
A HIV-1 proviral plasmid that expresses green fluorescent protein (GFP) in place
of Nef has been described previously (Zhang et al., 2002). 293T cells were
-52-

seeded in 10 cm plates at a concentration of 3 x 106 cells/plate and were
cotransfected the following day using polyethylenimine (PolySciences) with 10 μg
of wild-type (HIV-1(WT)) or Vpu-deficient (HIV-1(∆Vpu)) GFP reporter plasmids,
along with 1μg of a VSV-G expression plasmid. The culture medium was
replaced the following day. At 48 hours post transfection, the culture
supernatants were harvested, clarified by centrifugation at 3000 rpm, and filtered
through a 0.2 µm PVDF membrane (Millipore). The viruses were stored at -80°C.
Infectious virus titers were determined by inoculating sub-confluent monolayers
of 293T cells that were seeded in 96 well plates at 30,000 cells/well with 100 µl of
serially diluted supernatants. At 48 hours post infection, the cells were dispersed
with trypsin, fixed in 4% paraformaldehyde and analyzed by flow cytometry.

Virion yield assays
293T cells were seeded in 24-well plates at a concentration of 2 x 105 cells/well
and were co-transfected the following day using polyethylenimine (PolySciences)
with 350ng of wild-type (HIV-1(WT)) or Vpu-deficient (HIV-1(∆Vpu)) proviral
plasmids along with varying amounts of a plasmid expressing tetherin, PV1, or
the panel of modified PV1-like proteins (25ng to 100ng). To monitor transfection
efficient, a plasmid expressing YFP (75ng) was also co-expressed in all samples.
In all transfection experiments, the total amount of DNA was held constant by
supplementing the transfection with an empty expression vector. The culture
medium was replaced the following day. At 48 hours post transfection, the culture
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supernatants were harvested, clarified by centrifugation at 3000 rpm, and filtered
through a 0.2 µm PVDF membrane (Millipore). Infectious virus yield was
determined by inoculating sub-confluent monolayers of HeLa-TZM cells that were
seeded in 96 well plates at 10,000 cells/well with 100 µl of serially diluted
supernatants. At 48 hours post infection, β-galactosidase activity was determined
using GalactoStar reagent, in accordance with the manufacturer’s instructions
(Applied Biosystems). Physical particle yield was determined by layering 700 µl
of the virion containing supernatant onto 1 ml of 20% sucrose in PBS followed by
centrifugation at 20,000xg for 90 minutes at 4˚C. Virion pellets were then
analyzed by Western blotting.

Recovery of trapped virions
Cells (HEK293T) stably expressing WT or engineered tetherin proteins were
infected with VSV-G-pseudotyped HIV-1(WT) or HIV-1(∆Vpu) GFP at 1 infectious
unit per cell in 10 cm dishes. The inoculum was removed 6 h later. At 48 hours
post transfection, the culture supernatants were harvested, clarified by
centrifugation at 3000 rpm, and filtered through a 0.2 µm PVDF membrane
(Millipore).

Physical

particle

yield

was

determined

as outlined

above.

Simultaneously, the cells were washed with Factor Xa reaction buffer (20 mM
Tris·Cl, pH 6.5; 50 mM NaCl; 1 mM CaCl2) and incubated with 50 µg of Factor Xa
in 5 ml of Factor Xa reaction buffer for 2 hours at 37˚C. Alternatively, the cells
were washed with subtilisin A buffer (10 mM Tris, pH 8.0; 1 mM CaCl2; 150 mM
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NaCl), and treated with 5 ml of 1 µg/ml of subtilisin A (Sigma) for 3 min at room
temperature. Subtilisin treatment was stopped using DMEM containing 10%
FCS, 5 mM PMSF, and 20 mM EGTA. Thereafter, the supernatants were
centrifuged, filtered and virions pelleted as described above, and the cells were
lysed for analysis of viral protein expression by Western blotting.

Peptide-N-glycosidase-F digestion of tetherin
Lysates of cell and liberated virions were denatured with 0.5% SDS at 100°C for
10 minutes and then treated with 1% NP-40 to neutralize the SDS. The lysates
were incubated with (or without) 500 U of peptide-N-glycosidase-F (New England
Biosciences) at 37°C for 3 hours. Thereafter, the reactions were quenched with
SDS-PAGE loading buffer and the samples were analyzed with western blotting.

Western blot assays
Pelleted virions and cell lysates were resuspended in SDS-PAGE loading buffer,
in the presence or absence of β-mercaptoethanol, and resolved on NuPAGE
Novex 4-12% Bis-Tris Mini Gels (Invitrogen) in MOPS running buffer. Proteins
were blotted onto nitrocellulose membranes (HyBond, GE-Healthcare) in transfer
buffer (25 mM Tris, 192 mM glycine). The blots were then blocked with Odyssey
blocking buffer and probed with mouse monoclonal anti-HIV-1 capsid (NIH),
rabbit polyclonal anti-HA (Rockland), mouse monoclonal anti-FLAG (Sigma) and
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mouse monoclonal anti-PV1 (Abcam) primary antibodies. For quantitative
western blotting, the bound primary antibodies were detected using fluorescently
labeled secondary antibodies (IRDye 800CW Goat Anti-Mouse Secondary
Antibody, IRDye 680LT Goat Anti-Rabbit Secondary Antibody and IRDye 680LT
Goat Anti-Mouse Secondary Antibody; LI-COR Biosciences). Fluorescent signals
were detected using a LI-COR Odyssey scanner and quantitated with Odyssey
software (LI-COR Biosciences).

Phylogenetic analyses
Sequences for Tetherin and PV1 genes were retrieved from Ensembl (Release
71) and their cDNA sequence was used to construct multiple alignments using
MUSCLE followed by manual refinement based on a translated amino acid
sequence. The multiple alignments were used to construct maximum likelihood
(ML) phylogenetic trees using RaxML version 7.2.8 with the following
parameters: rapid bootstrap analysis with 100 replicates under GTRCAT followed
by a ML search under GTRGAMMA to evaluate the final tree topology (-m
GTRCAT -# 100 -x 13 -k -f a). The PV1 tree was rooted using the platypus
sequence as out-group. The tetherin tree was estimated using a reduced
sequence alignment that is composed of the transmembrane and coiled-coil
domains (codons 22 to 133 of human tetherin), and it was finally midpoint rooted.
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Analysis of PV1 and Tetherin sequences
Analysis of introns and neutrally evolving sequences were carried out using the
mVISTA visualization tool for global sequencing alignments. FASTA and
annotated

sequence

files

were

uploaded

to

the

mVISTA

website

(http://genome.lbl.gov/vista/mvista/about.shtml). A VISTA-Point alignment was
generated and a screenshot of all the alignments was captured.
Maximum likelihood analysis on PV1 and Tetherin genes was performed using
CODEML from the PAML suite of programs. Due to the high divergence of the Nand C- termini of tetherin sequences across mammalian species, the following
analyses were performed on a reduced sequence alignment that is composed of
the transmembrane (TM) and coiled-coil domains (codons 22 to 133 of human
tetherin). Likelihood ratio tests were used to compare paired, nested models of
sequence evolution that allow, or do not allow, variable selective pressure among
sites (NSsites models 0 vs. 3), or positive selection (NSsites models 1 vs. 2 and
7 vs 8). The F3X4 model of codon frequencies was used for all analyses in
CODEML. The chi-square test was performed using 4 degrees of freedom for M0
vs. M3 or 2 degrees of freedom for M1 vs. M2 and M7 vs. M8. The degrees of
freedom are based on the number of parameters for each model. For both PV1
and tetherin alignments used, sites where only one or two taxa contain data (i.e.
the vast majority of the sites contain gaps) were removed from the alignment.
The platypus sequence was also removed from the PV1 sequence alignment
used in this analysis.
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In silico evolution
The ancestral PV1 root sequence was inferred using BASEML from the PAML
suite of programs under the REV (GTR) model of nucleotide substitutions. We
allowed the ancestral PV1 sequence to evolve under distinct neutral substitution
rates for a period of 18.5 MY using the EvolveAGene 3 software with the
following parameters: two taxa, 0.05 mean branch length, no selection against
amino acid replacements and no selection against insertions/deletions (-n2 b0.05 -a1 -i1 -d1). The EvolveAGene 3 software selects against frameshift
insertions/deletions and non-sense mutations allowing us to obtain sequences
that maintained full coding capacity. The EvolveAGene 3 output for one run is
composed of two sequences where the actual length of each branch will be a
random number between 0 and twice the mean branch length selected. A Perl
script was written to collect the output of 100 sequences for each neutral
substitution rate. Thereafter, the original ancestral PV1 sequence and each of the
100 sequences per neutral substitution rate used were utilized as input for SeqGen [29] to simulate tetherin evolution for the remaining mammalian tree (using a
tetherin phylogenetic tree constructed from a full length tetherin multiple
sequence alignment as input). Parameters for Seq-Gen were estimated by
ModelTest using the Bayesian Information Criterion (BIC) likelihood test on a
previously constructed full length tetherin multiple sequence alignment. The BIC
likelihood ratio test selected the following parameters: HKY+G model; nucleotide
frequencies of 0.2519, 0.2668, 0.3012 and 0.1801 for A, C, G and T,
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respectively; alpha (for the shape of the gamma rate heterogeneity distribution) =
1.4289; proportion of invariable sites = 0.0039, transition-transversion ratio =
1.0225 (-mHKY -n100 -f0.2519,0.2668,0.3012,0.1801 -a1.4289 -i0.0039 t1.0225). For each sequence used as input, Seq-Gen produced 100 simulated
tetherin data sets (each data set is composed of simulated sequences
representing the taxa diversity of the tetherin phylogenetic tree used as input).
Thus, for each substitution rate used we obtained 10,000 in silico-evolved data
sets. For each data set, we compared the simulated sequences for human,
mouse and dog with the contemporary PV1 protein sequences using tBLASTn.

Identification of PV1/Tetherin-like proteins
All 105,281 human and 54,447 mouse annotated protein sequences were
downloaded from Ensembl (Release 71) using BioMart. A Perl script was written
to automate a pipeline to find protein sequences that contain one TM domain
followed by coiled-coil domains. Protein sequences were scanned for TM
domains using tmhmm 2.0. Sequences with only one TM domain and a
probability > 0.5 were selected and scanned for coil-coiled segments C-terminal
to the TM domain using COILS (probability > 0.5). A complete list of all human
and mouse gene locations was retrieved from Ensembl (Release 71) using
BioMart. A Perl script was written to compare the locations of the resulting
PV1/Tetherin-like proteins and the entire gene location list to establish the
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identity of the adjacent genes. Homology between PV1/Tetherin-like proteins that
are adjacent to each other was established by BLASTp searches.

Reconstruction of the PV1 locus
The PV1 loci across animals were retrieved using the Genome Browser
(http://genome.ucsc.edu/index.html) at the University of California at Santa Cruz
and synteny across eutherian mammals was assessed using the Genomicus
Browser

(http://www.genomicus.biologie.ens.fr/genomicus-70.01/cgi-

bin/search.pl). The tetherin protein in opossums and PV1 proteins in reptiles and
amphibians were not annotated in Ensembl and UCSC Genome Browser and
were identified using orthologous protein queries from closer related species in
BLAT searches.
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Chapter III Mechanism of HIV-1 virion entrapment by tetherin
In the following chapter, we describe the development of biochemical
approaches to dissect the molecular mechanisms that underpin the antiviral
activity of tetherin against enveloped viruses such as HIV-1. Investigations into
the role of tetherin heretofore have been hampered by the dearth of experimental
tools that probe tetherin molecules that have infiltrated the envelopes of
assembling viral particles. To address this, we used a combination of
biochemical assays and engineered tetherin proteins to specifically probe
tetherin molecules as they engage in virion entrapment. The results presented
herein have been published in a research article (Venkatesh and Bieniasz,
2013), which was the first study in the literature to demonstrate unequivocally
that tetherin is directly responsible for the retention of virions at the cell surface.
In particular, these biochemical analyses have been invaluable in elucidating the
configurations that tetherin homodimers adopt during HIV-1 restriction.

Putative configurations that might be adopted by tetherin during HIV-1 virion
entrapment
It is now well-established that the cellular restriction factor, tetherin, prevents
HIV-1 and other enveloped virus particles from being disseminated into the
extracellular milieu by infiltrating their envelopes and by physically crosslinking
them to the cell surface. However, the mechanism by which tetherin traps virions
is poorly understood. As described in the Introduction (Chapter 1), a
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preponderance of the evidence seem to support the notion that tetherin traps
virions via a direct tethering mechanism, i.e. by infiltrating the lipid envelope of
assembling particles (Fitzpatrick et al., 2010; Hammonds et al., 2010; PerezCaballero et al., 2009). Previous biochemical (Perez-Caballero et al., 2009) and
structural analyses (Hinz et al., 2010; Schubert et al., 2010; Swiecki et al., 2011;
Yang et al., 2010) suggest that tetherin consists of two pairs of membrane
anchors that are spatially separated by rod shaped coiled-coil domains. Although
the exact configuration adopted by the tetherin protein is still unknown, its unique
architecture does lend itself to a number of possibilities. For instance, one can
envisage a scenario wherein a pair of anchors partitions into the lipid envelope of
assembling particles, whilst the other pair remains rooted in the plasma
membrane of the infected cell (axial configuration, Figure 3.1A). In this
configuration, each tetherin dimer could potentially link viral and cell membranes
in either “polarity”, i.e. with N-termini inserted into either the infected cell or the
assembling particle. Other obvious possibilities by which entrapment might be
achieved would be via the separate partitioning of dimerized tetherin molecules
into virion and cell membranes (equatorial configuration, Figure 3.1B) or the noncovalent oligomerization of tetherin dimers that have both pairs of anchors
embedded in either virion envelopes or cell membranes (Figure 3.1C). In order to
dissect the molecular mechanisms that underpin the antiviral activity of tetherin,
we asked the following questions: (i) Is tetherin directly responsible in trapping
virions? (ii) Which, if any, of the aforementioned configurations are adopted
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Figure 3.1. Models illustrating the possible configurations adopted by
tetherin during virion entrapment. (A) Tetherin dimers might trap virions at the
cell surface via the infiltration of one pair of membrane anchors into the viral
envelope, while the other pair remains rooted in the infected cell membrane
(axial configuration). ‘N’ and ‘C’ represent the N- and C- termini of tetherin,
respectively. (B) Tethering might also be achieved through the separate
partitioning of dimerized tetherin molecules into virion and cell membranes
(equatorial configuration). (C) Tethering might be mediated by the non-covalent
association of tetherin dimers that have both pairs of anchors embedded in virion
envelopes or cell membranes.
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during the retention of virions, and, (iii) Does the contribution of any one
configuration outweigh that of the others?

A panel of modified tetherin proteins designed to deduce the configuration of
tetherin during HIV-1 virion entrapment
To address the above questions, we set out to develop genetic and biochemical
tools to probe tetherin molecules that have infiltrated tethered virions. It should
be noted that a variety of approaches, including hydropathy analyses, fusion with
reporter enzymes, or the insertion of target sites for proteases, antibodies and
chemical modifiers, have been used to deduce integral membrane protein
topology (Manoil et al., 1988). For example, the insertion of Factor Xa cleavage
sites into hydrophilic loops has proven to be useful for such investigations (Ota et
al., 1998; Wilkinson et al., 1996). Factor Xa is an endopeptidase that recognizes
the tetrapeptide motif Ile-Glu-Gly-Arg with strict specificity and cleaves the
protein backbone C-terminal to the arginine residue. To clarify the configuration
of tetherin molecules in infected cell and viral membranes, we adapted the
aforementioned approaches by engineering modified human tetherin proteins
that carried (i) single cleavage sites for Factor Xa and (ii) epitopes such as
hemagglutinin (HA) and FLAG tags positioned either N- or C-terminal to the
Factor Xa site (Figure 3.2). Importantly, previous experiences with tagged
versions of tetherin proteins led to the expectation that such minor alterations
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Figure 3.2. Schematic representation of the panel of modified tetherin
proteins designed to deduce the configuration of tetherin during HIV-1
virion entrapment. The C8 and N5 proteins have linker sequences inserted at
the C- and N-terminus of the tetherin extracellular domain, respectively. The
Factor Xa cleavage site is indicated by scissors, and the cysteine residues that
stabilize homodimerization are indicated as lines. Diagrams were constructed
using PDB entry 3MQC to represent the tetherin extracellular domain.
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should have either no or modest effects on antiviral activity (Neil et al., 2008;
Perez-Caballero et al., 2009).
Initial experiments in which Factor Xa sites alone were incorporated into Tetherin
resulted in proteins that were somewhat refractory to proteolysis (unpublished
observations). Hence, we reasoned that the introduction of flexible linkers into its
primary sequence might facilitate access to the cleavage site, and increase the
efficiency of proteolysis. To test this hypothesis, we generated a panel of linker
modified tetherin proteins in which we inserted two, five and eight GGGGS
peptide linker units into the extracellular domain of tetherin, either N-terminal (at
amino acid 50) or C-terminal (at amino acid 157) to the predicted coiled-coil
domain. The GGGGS pentapeptide is predicted to be unstructured because the
glycine residues impart flexibility, and the polar serine residue permits hydrogen
bonding to the solvent (Argos, 1990; Huston et al., 1991). As an initial line of
inquiry, this panel of proteins was screened for their ability to inhibit replicationcompetent HIV-1, in order to identify candidate proteins for the insertion of the
Factor Xa site.

Antiviral activity of modified tetherin proteins
Among the panel of linker modified tetherin proteins, we determined that the
proteins with eight linker units C-terminal to the coiled-coil (C8, Figure 3.2) and
five linker units N-terminal to the coiled-coil (N5, Figure 3.2) were expressed at
comparable levels to WT tetherin (Figure 3.3). Note that Tetherin is
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Figure 3.3. Expression profiles of the panel of modified tetherin proteins.
Western blot analyses of the 293T cell lysates that were co-transfected with a
Vpu-deficient (HIV-1 ∆Vpu) proviral pNL4-3 plasmid along with varying amounts
of the indicated modified tetherin proteins. All samples were lysed in nonreducing buffer and probed with an anti-HA antibody.
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heterogeneously glycosylated, and because the cells were lysed in non-reducing
buffer, the tetherin proteins migrated primarily as a smear of dimeric species
(Perez-Caballero et al., 2009) (Figure 3.3).
To examine the antiviral activity of the linker-modified tetherin proteins, 293T
cells were transfected with either a HIV-1 proviral plasmid (HIV-1(WT)) or its
Vpu-deficient counterpart (HIV-1(∆Vpu)), along with varying amounts of plasmids
expressing wild type (WT) tetherin or one of the modified tetherin proteins. 293T
cells were chosen because they are a tetherin-negative cell line. Hereafter, WT
tetherin (Figure 3.2) refers to a previously described construct that harbors an HA
epitope tag at amino acid 155 in the extracellular domain, but retains the antiviral
activity of the untagged, endogenous protein (Neil et al., 2008). As expected, WT
tetherin potently inhibited the release of HIV-1 (∆Vpu) in a dose-dependent
manner, while only marginally affecting the release of HIV-1 (WT) (Figures 3.4A
and 3.4B). Importantly, the C8 and N5 tetherin proteins were only modestly
impaired in their antiviral activity compared to WT tetherin as determined by
infectious virion yield and extracellular particulate CA protein measurements
(Figures 3.4A and 3.4B) and the levels of cell-associated Gag protein were
unaffected by the expression of the tetherin proteins (Figure 3.4B). This data
indicates that the insertion of linker sequences into tetherin was well tolerated
with little effect on antiviral activity.
We next programmed the C8 and N5 tetherin proteins with single Factor Xa
cleavage sites. The rationale was that these proteins (referred to hereafter as
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Figure 3.4. Antiviral activity of the panel of modified tetherin proteins. (A)
Schematic representation of the experimental strategy to determine the antiviral
activity of the modified tetherin proteins. (B) 293T cells were cotransfected with
wild-type (HIV-1 (WT)) or Vpu-deficient (HIV-1 ∆Vpu) proviral pNL4-3 plasmids
along with varying amounts of the indicated modified tetherin proteins. Infectious
virion yield was measured by inoculating HeLa-TZM indicator cells with culture
supernatant and is given as the logarithm to the base 10 of the relative light units
(RLU). (C) Western blot analyses of transfected 293T cell lysates and virions
corresponding to the above panel. All samples were probed with an anti-CA
antibody. The numbers at the bottom represent measurement of CA protein
levels in virion pellets (LI-COR).
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C8Fac and N5Fac respectively, Figure 3.2) would differ in the relative ordering of
the HA epitope tag and the protease site. Thus, the epitope tag is positioned Nterminal to the protease site in the C8Fac protein, whereas it is positioned Cterminal to the protease site in the N5Fac protein. In addition to the C8Fac and
N5Fac proteins that carried only one epitope tag, we also appended the Nterminus of the N5Fac construct with three tandem FLAG epitope tags. This
manipulation results in FLAG and HA epitope tags flanking the protease site
(Flag N5Fac, Figure 3.2). The use of three FLAG tags in tandem reportedly
enhances signal intensity by ~10-20-fold (Hernan et al., 2000).
Analysis of the antiviral activity of the Factor Xa site-modified tetherin proteins
revealed that the C8Fac and N5Fac proteins were only slightly impaired in their
ability to trap virions as compared to WT tetherin, while the Flag N5Fac protein
was nearly indistinguishable its activity to WT tetherin (Figures 3.4A and 3.4B).
Western blotting analyses of the C8Fac and N5Fac proteins indicated that they
were expressed at slightly lower levels than the C8 and N5 proteins respectively
(Figure 3.3), and were thus proportionately impaired in antiviral activity (Figures
3.4A and 3.4B). Interestingly, in spite of harboring more tags as compared to any
of the other modified tetherin proteins, the Flag N5Fac protein was virtually as
potent as WT tetherin, and was expressed at levels indistinguishable from WT
tetherin. Vpu antagonized all modified tetherin proteins and restored the yield of
extracellular virions (Figures 3.4A and 3.4B). Thus, all modified tetherin proteins
mimicked WT tetherin, i.e. they trapped virions, and were sensitive to the action
of HIV-1 Vpu.
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Antiviral activity of modified tetherin proteins in stable cell lines
Thus far, the antiviral activity of the panel of modified tetherin proteins was
analyzed using transient transfection assays. In principle, transient transfections
yield high expression levels of the protein over short time intervals, after which
the plasmids are rapidly lost during cell division. It should be noted that the
results from a transfection assay should be interpreted with caution because only
a fraction of the cells in culture tend to bias most of the observed phenotype.
Another confounding factor is the high expression levels of the protein that is not
physiologically relevant. Such issues are ameliorated by the use of stable
transduction assays, wherein every cell in culture expresses lower levels of the
protein. Furthermore, stable cell lines selected through limited dilution provide a
genetically homogenous and clonal population.
To confirm and extend our observations, we generated a panel of 293T cells that
stably expressed the epitope-tagged Factor Xa-cleavable tetherin proteins. The
levels of cell surface tetherin in these stable cell lines was assessed by flow
cytometry using a monoclonal antibody that recognizes the extracellular region of
human tetherin. Importantly, the surface expression levels of the WT and
modified tetherin proteins were quite similar to each other, varying over a 2.5-fold
range (mean fluorescent intensities were 6200, 15000, 8800, and 12000 for WT,
C8Fac, N5Fac and Flag N5Fac tetherin proteins, respectively; Figure 3.5A) and
were only 1.5 to 3-fold greater than that of the endogenous protein in HeLa cells,
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Figure 3.5. Antiviral activity of modified tetherin proteins in stable cell lines.
(A) 293T cells that stably express the modified tetherin proteins were analyzed
by flow cytometry to determine the relative surface expression levels of tetherin,
using a mouse anti-human tetherin antibody. (B) Western blot analyses of the
stable 293T cell lysates and virions harvested from them, following infection with
HIV-1 or its Vpu-deficient counterpart at a MOI of 1. All samples were probed
with an anti-CA antibody. The three lanes for each tetherin protein are replicates
of the experiment.
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a prototype tetherin-positive cell line (mean fluorescent intensity =5000; Figure
3.5A).
We next verified the antiviral activity of the engineered tetherin proteins in the
stable cell lines using single-cycle HIV-1 replication assays (Figure 3.5B). The
stable cells were infected with HIV-1 or its Vpu-deficient counterpart, with both
viruses harboring the GFP protein for quantification of infected cells. Control cells
that stably expressed the empty vector were also included for the purpose of
comparison. As expected, both the WT and the modified tetherin proteins
inhibited the release of particles from infected cells, but did not affect cell
associated Gag protein expression (Figure 3.5B). Moreover, the expression of
Vpu reversed the inhibitory effect of the modified tetherin proteins, resulting in the
release of capsid protein into the supernatant (Figure 3.5B). Thus, it was
reassuring that the panel of stable cells recapitulated our transient transfection
results.

An assay to probe the configuration of tetherin during HIV-1 particle entrapment
Previous studies from our laboratory have employed a protease “stripping” assay
(Neil et al., 2006; Neil et al., 2007) in which a relatively nonspecific protease
(subtilisin A) was used to demonstrate that the ectopic expression of tetherin
causes virions to become entrapped on cell surfaces by a protein based tether.
The logic underpinning the “second generation” assay described herein is that if
the tetherin protein itself is directly responsible in trapping virions, then treatment
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of cell surfaces with a specific protease (Factor Xa) would trigger the release of
virions only when tetherin was programmed with a Factor Xa cleavable site
(Figure 3.6A). Moreover, cleavage should result in partitioning of the epitopetagged proteolytic fragments either into the liberated virions or the infected cells.
Because the epitope tags were strategically positioned relative to the protease
site, topological information could then be deduced about tetherin in its functional
state (Figure 3.6B). However, it is expected that only a minority of the tetherin
molecules on the cell surface would actually be involved in tethering virions, and
hence, only fragments that are found in virions should be regarded as informative
with respect to tetherin topology during virion entrapment. Nevertheless, we also
assessed the proteolytic cleavage of the tetherin proteins in whole cell lysates for
multiple reasons. First, tetherin molecules that are en route to the cell surface
would be insensitive to the action of Factor Xa, which is cell-impermeable. If not,
one could infer that Factor Xa treatment is resulting in undesirable cell lysis.
Second, it is obviously important that the size of the cleaved proteolytic
fragments in cells should exactly match that in the liberated virions, if indeed
tetherin cleavage is necessary for liberation of virions.
Note that if tetherin adopts the equatorial configurations depicted in Figure 3.1B
or 3.1C then we would not expect Factor Xa cleavage to result in virion release,
because the cleavage sites are positioned outside the region of coiled-coil
interaction. Indeed, the cleavage sites are positioned in artificially introduced
linker sequences whose insertion did not perturb tetherin function (Figures 3.2
and 3.4). Conversely, if tetherin adopts the axial configuration in virion tethers,
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Figure 3.6. A biochemical assay to probe the configuration and polarity of
tetherin homodimers that are engaged in virion entrapment. (A) Schematic
representation of the protease-induced virion release assay. Modified tetherin
dimers programmed with a protease cleavage site (scissors) are indicated as
orange helices, while the WT tetherin dimers are indicated as green helices. If
trapped viruses are liberated upon protease treatment only when tetherin is
programmed with a protease site, it confirms a role for tetherin as a direct tether
in virion entrapment. The liberated virions are subjected to quantitative western
blotting analyses to estimate the numbers of tetherin dimers associated with a
single virion and their orientation. (B) Schematic representation of the polarities
that would be adopted by the C8Fac and N5Fac proteins if HA-tagged proteolytic
fragments are observed to partition with liberated virions.
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then Factor Xa cleavage should result in virion release. Moreover, if as depicted
in Figure 3.6B, the HA-tagged proteolytic fragments partition with virions that are
liberated from Factor Xa-treated, C8Fac-expressing cells, it would suggest that
tetherin dimers exist with their N-termini inserted into the interior of the virion.
Conversely, if HA-tagged proteolytic fragments partition with virions that are
liberated from the N5Fac cell line, we would deduce that tetherin dimers exist
with their GPI anchors embedded in the virion membrane (Figure 3.6B). If,
however, tetherin dimers adopt both polarities, then HA-tagged proteolytic
fragments would be observed in virions liberated by Factor Xa from both C8Fac
and N5Fac expressing cell lines.
We first investigated the utility of this approach using cell lines expressing the
single epitope tagged C8Fac and N5Fac tetherin proteins. Cells were infected
with Vpu-deficient HIV-1, and constitutively released particles were harvested
from culture supernatants at 48h post infection. Thereafter, the monolayer of
cells was treated with Factor Xa for 2h, and then the cell lysates and any
liberated virions were also harvested. The amount of Factor Xa and the
incubation time were determined empirically. Samples were removed at various
time points and analyzed to estimate the extent of Factor Xa digestion. At 2h
post-treatment, the cleavage of Factor Xa-modified tetherin molecules was
complete.
As before, infected control tetherin-negative cells constitutively released
substantially high levels of virions into the culture supernatant, while virion yield
from cells expressing WT, C8Fac or N5Fac tetherin proteins was markedly
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reduced (Figure 3.7A). Importantly, the expression levels of HIV-1 Gag
expression in cell lysates were similar, indicating that levels of infection were
uniform across all samples (Figure 3.7A).
Incubation in Factor Xa cleavage buffer alone resulted in the release of only low
levels of pelletable CA from tetherin-deficient cells (Figure 3.7A). This might
represent virion particles that were constitutively released during the 2 hour
incubation period, or virions that were loosely adhered to the cell surface (Figure
3.7A). Even lower levels of particles were released from cells expressing the WT,
C8Fac or N5Fac tetherin proteins that were incubated in Factor Xa cleavage
buffer alone (Figure 3.7A). Strikingly however, Factor Xa treatment of the C8Fac
and N5Fac resulted in the release of substantial amounts of particulate CA
(Figure 3.7A). Crucially, Factor Xa treatment of tetherin-negative or WT tetherin
expressing cells did not increase particle release over the low background levels
that were observed in the absence of protease, underscoring the tight specificity
of the assay (Figure 3.7A). Notably, the proteolytic fragments of tetherin that
were observed in Factor Xa-liberated virions from both C8Fac and N5Fac
expressing cells and virion-associated fragments were consistent with dimer
formation, and were the only tetherin species that were detectable on nonreducing SDS PAGE gels (Figure 3.7A).
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Figure 3.7. Axially configured tetherin homodimers directly trap virions,
with both polarities contributing to restriction. (A) Western blot analyses of
virions, 293T cells stably expressing C8Fac and N5Fac tetherin proteins, and
virions liberated upon Factor Xa treatment. The samples were probed using antiHA and anti-CA antibodies. (B) Western blot analyses of PNGase-F-treated cells
and liberated virions from the above panel. The samples were probed using an
anti-HA antibody. Stars indicate non-specific bands.
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Because tetherin is intrinsically heterogeneous, due to variable glycosylation as
well as dimer formation, it was difficult to assess the extent of Factor Xa cleavage
in cell lysates (Figure 3.7A, cell lysates), or to unambiguously demonstrate that
only cleaved tetherin fragments were present in Factor Xa liberated virions
(Figure 3.7A, Factor Xa liberated virions). Therefore we treated cell and virion
lysates with Peptide-N-Glycosidase F (PNGase-F) and repeated the western blot
analyses

under

reducing

conditions

(Figure

3.7B).

PNGase-F

is

an

endoglycosidase that cleaves between the innermost GlcNAc and asparagine
residues of high mannose and complex oligosaccharides from N-linked
glycoproteins (Maley et al., 1989). We observed that the HA-tagged proteolytic
fragments (predicted molecular weights of ~20.8 kDa and ~17 kDa for C8Fac
and N5Fac respectively) could be resolved from the full-length molecules (~24.7
kDa and ~23.8 kDa for C8Fac and N5Fac respectively) (Figure 3.7B). This
analysis revealed that about half of the cell-associated C8Fac and N5Fac protein
was cleaved by Factor Xa that was applied to the cell surface (Figure 3.7B). The
incomplete cleavage may have been due to the intracellular localization of a
fraction of the tetherin protein. As expected, no proteolysis of the WT tetherin
protein was observed (Figure 3.7B). Notably, only the cleaved tetherin protein
was found in PNGase-F-digested virion lysates, consistent with the notion that
tetherin cleavage by Factor Xa was necessary for virion release in this assay
(Figure 3.7B).
Overall, these results strongly suggested that tetherin is directly responsible in
trapping virions, and that it does so by adopting the axial configurations depicted
-86-

in Figure 3.1A. Moreover, because HA-tagged proteolytic fragments from both
C8Fac and N5Fac tetherin proteins partitioned with virions, these data suggested
that both polarities depicted in Figure 3.1A are adopted during virion entrapment.

Estimates of the number of tetherin dimers that are required to trap a single virion
Because our biochemical analyses are devised to capture tetherin molecules in
the act of retaining virions, we surmised that it would be possible to obtain
reasonable estimates of the number of tetherin dimers that were involved in the
entrapment of a single virion. Towards that purpose, we employed a quantitative
western blotting approach and PNGase-F-digested virion lysates to measure the
relative number of CA and HA epitopes in virions that had been trapped by the
C8Fac and N5Fac proteins, and then liberated upon Factor Xa cleavage. First,
we generated an appropriate internal standard protein to enable relative
quantitation. This standard consisted of a fusion protein that comprised the HIV-1
p24CA protein, appended at its C-terminus with three tandem FLAG tags and an
HA epitope tag. Thus this single protein included each of the epitopes that we
planned to probe, at a stoichiometric ratio of 1:1:1 and could be used as a
standard to compare the relative numbers of HA and CA epitopes in tethered
virions released from C8Fac and N5Fac expressing cells. Specifically, serial
dilutions of cell lysates expressing the HA-Flag-CA protein were run on SDSPAGE gels, blotted onto membranes and probed with antibodies against CA and
HA. The band intensities were analyzed using a LiCOR Odyssey scanner
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(Figures 3.8A and 3.8B), and regression analysis was performed over the linear
range of signal intensities (Figures 3.8A and 3.8B). Dilutions of the PNGase-Ftreated virion lysates recovered from C8Fac and N5Fac expressing cells that
also yielded band intensities in the linear range of the assay were resolved on
the same gel as the standard, and the relative amounts of CA and HA epitope in
each samples were deduced by interpolation using the standard curves (Figures
3.8A and 3.8B).
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Figure 3.8. Quantitative Western blot analyses of Factor Xa-liberated
virions. (A) Western blot analyses of serially diluted lysates of 293T cell
expressing the CA-HA-Flag protein along with the PNGase-F-treated, Factor Xaliberated virion lysates (top panel). The samples were probed with an anti-CA
antibody. The CA band intensities for the control protein were analyzed using a
LiCOR Odyssey scanner and were plotted against the dilution (lower left panel).
Regression analysis was performed over the linear range of signal intensities
(lower right panel) and the unknown amounts of CA in the PNGase-F-treated
liberated virion lysates were deduced by interpolation of the standard curve. (B)
Same as (A), except that the samples were probed with an anti-HA antibody.
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HIV-1 virions have been reported to contain between 1000-5000 copies of the
Gag protein, of which only a fraction contributes to core formation (Briggs et al.,
2004; Layne et al., 1992; Piatak et al., 1993; Vogt and Simon, 1999; Zhu et al.,
2003). We calculated our estimates of tetherin dimers per virion based on the
extremities of this range (Table 3.1). Thus, if each virion contains 1000 CA
protein molecules, we estimate that 16±5 dimers of the N-terminus of C8Fac and
71±26 dimers of the C-terminus of N5Fac tetherin dimers were associated with a
single tethered virion (Table 3.1). Conversely, if a single virion contains 5000 CA
epitopes, then we estimate that 80±25 dimers of the N-terminus of C8Fac and
355±130 dimers of the C-terminus of N5Fac tetherin dimers were associated with
a single tethered virion (Table 3.1). Essentially, these estimates suggested a
preference (~4 to 5-fold) for the insertion of the GPI-anchored tetherin Cterminus, rather than the N-terminal transmembrane domain into virions (Figure
3.6B). Note that the larger number of HA tags associated with virions in the case
of N5Fac cannot be explained by differences in tetherin expression levels. In fact,
there were slightly lower levels of N5Fac on cell surfaces (MFI = 8800, Figure
3.5A) as compared to the C8Fac protein (MFI = 15000, Figure 3.5A).
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Table 3.1. Quantitative Western blotting analyses of virions tethered by the
C8Fac and N5Fac proteins.
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Preferential insertion of tetherin C-termini into HIV-1 particles during virion
entrapment
The aforementioned experiments indicated that tetherin directly tethers HIV-1
particles in an axial configuration (Figure 3.1A) and suggested that both polarities
contribute to antiviral activity. However, it was possible that the two different
estimates for the numbers of tetherin molecules inserted into virions with each
polarity might reflect intrinsic differences in the properties of the two different
tetherin molecules used (C8Fac and N5Fac). Therefore, we quantitated tetherin
insertion into virions in a second set of experiments employing a single tetherin
molecule that harbored two different epitope tags flanking the Factor Xa cleavage
site (Flag N5Fac, Figure 3.2).
Additionally, we have previously found that Vpu-defective HIV-1 virions that
accumulate on the surface of cells as a result of the action of tetherin can
sometimes be tethered to each other as well as to the cell surface (Neil et al.,
2008; Perez-Caballero et al., 2009) (Figure 3.9). This scenario could well be the
result of virion assembly at sites on the cell surface already occupied by trapped
virions, which would result in both anchors of a tetherin molecule becoming
incorporated into assembling particles (Figure 3.9). It should be noted, however,
that chains of tethered virions are typically observed in EM experiments wherein
cells are infected at high MOIs (>5) and might thus be an experimental artifact
(Figure 3.9). Over time, the accumulation of virions could potentially mask the
propensity of either one of the N-or C-termini of the tetherin protein to be
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Figure 3.9. Schematic representation of the budding of HIV-1 viral particles.
Because virions are not only linked to the plasma membrane, but to each other,
tetherin molecules incorporate both anchors into trapped virions. Thus, a
preference for inserting the C-terminal GPI anchor into virions during particle
assembly would eventually get lost over time.
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preferentially inserted into virions (Figure 3.9). Thus, we treated the surface of
cells expressing Flag N5Fac with Factor Xa at predetermined time intervals
following infection with HIV-1∆Vpu, and quantified HA- and FLAG-tagged
proteolytic fragments in liberated virions.
The Factor Xa site is positioned N-terminal to the sites of N-linked glycosylation
as well as to the extracellular cysteine residues in the Flag N5Fac molecule
(Figures 3.2 and 3.10A). We observed that Factor Xa cleavage of the 65-70 kDa
dimeric, glycosylated Flag N5Fac protein yields a cell associated dimeric,
glycosylated ~50-55 kDa α-HA reactive species as well as a cell associated
monomeric, nonglycosylated 10 kDa α-FLAG reactive species (Figure 3.10B).
This is intuitive given that the extracellular and intracellular redox environments
are non-reducing and reducing respectively. The HIV-1 Gag protein became
detectable in infected Flag N5Fac-expressing cell lysates at ~24h after infection
and levels progressively increased with time thereafter (Figure 3.10B). Treatment
of these infected cells with Factor Xa resulted in a time dependent increase in the
amount of recovered virions (Figure 3.10B). Notably, both the dimeric
glycosylated ~50-55 kDa α-HA reactive species and the 10kDa α-FLAG reactive
species were observed in virions, and their levels in the virion fraction increased
with time, approximately in parallel with the increasing yield of Factor Xa
liberated virions (Figure 3.10B).
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Figure 3.10. Factor Xa-induced liberation of virions trapped by the
FlagN5Fac tetherin protein. (A) Schematic representation of the polarities that
would be adopted by the Flag N5Fac protein if HA- or FLAG-tagged proteolytic
fragments are observed to partition with liberated virions. (B) Western blot
analyses of 293T cells and liberated virions, obtained by the protease treatment
of Flag N5Fac cells at various time points following infection. The samples were
probed using anti-HA, anti-FLAG and anti-CA antibodies.

-96-

A

-97-

B

-98-

It is interesting that the N-terminal FLAG tagged fragment of the Flag N5Fac
protein was also found in virions in a form that was consistent with the formation
of dimers (Figure 3.10B). We hypothesize that the cytoplasmic tail of tetherin
contains two cysteine residues that might form disulphide bonds in the interior of
virions, which is presumably an oxidizing environment. Consistent with this idea,
only the smaller of the two Flag tagged species was observed when virion
lysates were subjected to SDS PAGE gel electrophoresis under reducing
conditions (Figure 3.11A). Additionally, the dimeric glycosylated ~50-55 kDa αHA reactive species collapsed to a single ~17 kDa band when samples were
deglycosylated with PNGase and reduced (Figure 3.11A).
We used quantitative western blot analyses of PNGase-F-digested virion lysates
to estimate the number of copies of HA- and FLAG-tagged proteolytic fragments
per trapped virion (Figures 3.11A and 3.11B). Again, we used the FLAG-HA-CA
fusion protein as an internal standard to determine the relative numbers of HA,
FLAG and CA epitopes in the virions liberated from Flag N5Fac expressing cells.
We observed that tethered virions could be recovered from the surface of Flag
N5Fac expressing cells beginning at 24h after infection, i.e. when the HIV-1 Gag
protein was detectable in cell lysates. However, we could not make reliable
estimates of the HA and FLAG fragments at this time point, as they were present
at low levels that were close to the limit of detection. We were able to make
reasonably robust estimates of the levels of incorporation of HA- and FLAGtagged fragments into virions beginning at 32h after infection (Figures 3.11A and
3.11B).
-99-

Figure 3.11. Quantitative Western blot analysis of Factor Xa-liberated Flag
N5Fac virions. (A) Western blot analyses of 293T cells expressing serial
dilutions of the CA-HA-Flag protein and the PNGase-F-treated liberated virion
lysates. The samples were probed with anti-CA, anti-HA and anti-FLAG
antibodies. (B) The CA, HA and FLAG band intensities were determined using a
LiCOR Odyssey scanner and were plotted against the dilutions (left panels).
Regression analysis was performed over the linear range of signal intensities
(right panels), and the unknown amounts of CA, HA and FLAG epitopes in the
PNGase-F-treated, Factor Xa-liberated virion lysates were deduced by
interpolation from the standard curves.
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Crucially, the number of FLAG-tagged dimers that were estimated to be present
in virions (assuming 1000 CA molecules per virion) tethered by Flag N5Fac
(11±3 [at 32h] to 16±6 [at 48h], Table 3.2) correlated quite well with the number
of HA-tagged dimers present in virions tethered by C8Fac (16±5 [at 48h], Table
3.1). Similarly, the number of HA-tagged dimers in tethered virions recovered
from the Flag N5Fac expressing cells (34±18 [at 32h] to 55±28 [at 48h]) (Table
3.2) correlated quite well with the number of copies of HA-tagged dimers in
tethered virions recovered from the N5Fac expressing cells (71±26 at 48h)
(Table 3.1). These data suggested that our earlier analyses could not have been
biased by intrinsic differences between the C8Fac and N5Fac molecules.
In particular, we estimated that the virions liberated from Flag N5Fac expressing
cells carried ~3 to 4-fold more HA tags than FLAG tags, again suggesting that
axially configured tetherin dimers infiltrate assembling particles, with a modest
tendency to embed their C-termini rather than their N-termini in liberated virions.
Also noticeable was a marginal trend for the appearance of increasing numbers
of tetherin molecules per virion over time. This trend was not statistically
significant and could be due to some unknown bias in the measurements.
Another interpretation is that virions with fewer numbers of tetherin molecules are
constitutively released, leading to the accumulation of virions with greater
numbers of tetherin molecules on the surface of cells.
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Table 3.2. Quantitative Western blotting analyses of virions tethered by the
Flag N5Fac protein.

-104-

Efficient proteolysis and liberation of virions by Factor Xa
One potential caveat of our experiments is that alternate configurations of
tetherin might exist that are resistant to the action of Factor Xa. For instance,
higher order configurations of tetherin that are tightly packed might limit the
accessibility of Factor Xa to its cleavage site. Such subpopulations of tetherin
would then continue to trap virions at the cell surface, and would be unaccounted
for in our analyses. To investigate this further, we treated the stable cells
expressing the panel of modified tetherin proteins with Factor Xa or subtilisin A,
and compared the yield of liberated virions via western blotting analyses.
Because subtilisin A works rather non-specifically, it is expected to degrade all
configurations of tetherin and would thus release all trapped virions.
Reassuringly, we observed that similar levels of virions were liberated by Factor
Xa as compared to subtilisin A at 48h after infection for all the modified tetherin
proteins (Figure 3.12). These findings suggest that Factor Xa is efficient at
liberating virions from the cell surface and discount the likelihood that
alternatively configured tetherin molecules continue to trap virions.
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Figure 3.12. Efficient proteolysis and liberation of virions by Factor Xa.
Western blot analyses of 293T cells stably expressing the modified tetherin
proteins and virions liberated upon Factor Xa or subtilisin A treatment. All
samples were probed using an anti-CA antibody.
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The ESCRT pathway is dispensable for virion entrapment
Previously, it has been hypothesized that various components of the ESCRT
pathway might be required for tetherin to carry out its biological activity,
presumably because they are active during similar stages of particle assembly
(Grover et al., 2013). However, an artificial tetherin construct that bears no
sequence homology to WT tetherin, is proficient at trapping virions, making it
highly unlikely that recognition of a cofactor is necessary for tetherin function
(Perez-Caballero et al., 2009). Furthermore, the ESCRT pathway is recruited to
sever the neck of the stalk that separates the cell and viral membranes, whereas
tetherin acts after budding and traps nascent virions whose membranes are
discontinuous with that of the infected cell membrane. Thus, the ESCRT pathway
and tetherin function at different stages of viral assembly and are not expected to
influence each other.
To resolve this controversy, we endeavored to determine if tetherin-mediated
virion entrapment was dependent on the ESCRT pathway. To that end, we asked
if tetherin is proficient at restricting virions that have been assembled from a
novel Gag protein and released thereafter in an ESCRT pathway-independent
fashion. Such a protein (ZWT-p6), in which the nucleocapsid and p1 proteins are
replaced with the leucine zipper domain of the yeast transcription factor Gcn4,
has the propensity to multimerize and form virus-like particles (VLPs) (Accola et
al., 2000) (Figure 13.3A). We also generated its p6-deficient counterpart (ZWT∆p6; Figure 13.3A) by substituting the start codon of p6 with a stop codon. Thus,
both the ZWT-p6 and ZWT-∆p6 proteins can assemble efficiently without the
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Figure 3.13. A minimal Gag protein bearing the leucine zipper domain of the
yeast transcription factor Gcn4 and lacking late domains is efficiently
restricted by wild type tetherin. (A) Schematic representation of the NL4-3
Gag construct and its derivative ZWT-p6 in which the nucleocapsid protein is
replaced by the leucine zipper domain. The ZWT-∆p6 has a stop codon that
abolishes p6 expression. The leucine zipper domain is indicated using red and
green helices. (B) Western blot analyses of 293T cell lysates and virions
generated following cotransfection of 293T cells with 150 ng of the indicated Gag
construct and increasing doses of tetherin plasmid. The samples were probed
with anti-CA and anti-HA antibodies.
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ESCRT pathway, but the ZWT-∆p6 protein is impaired in its ability to recruit the
ESCRT pathway (Figure 13.3A). The underlying logic is that the ESCRT pathway
would be dispensable if tetherin could restrict both Gag proteins with equal
efficiency. We included NL4-3 Gag as a control (Figure 13.3A).
All three Gag proteins were expressed by using a Vpu-deficient version of the
expression vector pCRV-1. pCRV-1 is a hybrid expression vector of pCR3.1 and
the HIV provirus V1-B. In this system, Gag, Rev and Tat are the only viral
proteins that are expressed. 293T cells were co-transfected with the panel of
Gag proteins along with varying doses of a plasmid expressing tetherin. The
expression levels of the Gag proteins were uniform in cell lysates, and the p6
lesion in ZWT-∆p6 was reflected by a protein of faster electrophoretic mobility
(Figure 13.3B).
In the absence of tetherin, there was a substantial accumulation of VLPs of all
three Gag proteins in the supernatant (Figure 13.3B). As expected, NL4-3 Gag
VLPs were potently restricted by tetherin in a dose dependent manner (Figure
13.3B). Notably, tetherin was equally efficient at trapping the ZWT-p6 and ZWT∆p6 VLPs as compared to NL4-3 VLPs (Figure 13.3B). Thus, this result indicates
that the ESCRT pathway is dispensable for virion entrapment.
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Crosslinking analyses to assess whether higher order multimers contribute to
virion entrapment
A number of structural studies have suggested that tetherin forms higher order
multimers (Schubert et al., 2010; Yang et al., 2010). However, as described in
the Introduction (Chapter 1), the functional relevance of higher order multimer
formation is strongly disputed. To determine whether higher order tetherin
multimers form, and whether they might contribute to tethering in equatorial or
axial configurations, we formulated an approach that coupled cysteine-scanning
mutagenesis and the Factor Xa stripping assay. Specifically, we generated a
panel of 19 tetherin proteins in which certain amino acid residues in the
extracellular coiled-coil domain of tetherin were substituted to cysteine. These
mutants were made in the C8Fac background to avail of the Factor Xa cleavage
site. Our mutagenesis strategy, guided by structural analyses (Yang et al., 2010),
targeted amino acids that are present on the exposed surfaces of the coiled-coil
domain. These amino acids can potentially promote the association of higher
order multimers via inter-dimer disulphide bridges between proximal cysteine
residues.
Our earlier efforts have already demonstrated that virions trapped by axially
configured tetherin molecules are liberated upon Factor Xa treatment. In
contrast, if higher order multimers exist, they would remain intact due to the
disulphide bridges and would only be disrupted upon β-mercaptoethanol (β-ME)
treatment (Figure 3.14A). Thus, cells that stably express the cysteine mutants
were treated with Factor Xa followed by β-ME and the yield of virions was
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Figure 3.14. Factor Xa-induced liberation of virions trapped by a
crosslinkable mutant of tetherin. (A) Experimental strategy to assess if the
tetherin molecules in the equatorial configuration contribute to HIV-1 virion
entrapment. HIV-1 virions that are trapped by axially configured tetherin
molecules would be released upon treatment of Factor Xa alone. Conversely,
equatorially configured tetherin molecules will only be released upon treatment
with Factor Xa followed by β-mercaptoethanol (β-ME). The cysteine residues that
drive inter-dimer interactions are indicated as black lines. (B) Western blot
analyses of 293T cell lysates following transfection with 150 ng of the indicated
plasmids. The samples were probed with an anti-HA antibody. (C) Western blot
analyses of virions, 293T cells stably expressing Fac4 and Q142C tetherin
proteins, and virions liberated upon Factor Xa and β-ME treatment and probed
using anti-CA and anti-HA antibodies.
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compared with control C8Fac cells (Figure 3.14A). The underlying rationale was
that if β-ME triggered the release of virions that were trapped by the cysteine
mutants, but not the C8Fac protein, then we could infer that tetherin molecules
configured as higher order multimers contribute to virion entrapment.
Initially, we expressed each mutant protein to screen for candidates that would
crosslink via inter dimer disulfide bridges. As a control, we also included the
parental non-crosslinkable C8Fac protein. We observed that one mutant, Q142C,
had the propensity to form higher order multimers (Figure 3.14B).
Next, we generated 293T cells that stably expressed the Q142C mutant and
performed an extended version of the Factor Xa stripping assay (Figure 3.14C).
Briefly, the cells were washed twice with Factor Xa buffer after harvesting Factor
Xa-liberated virions, treated with 0.1% β-ME for 5 minutes, and any liberated
virions were harvested. Note that this concentration of β-ME is low enough that it
is not expected to cause cell lysis (Binley et al., 2000).
As before, infected tetherin-deficient cells constitutively released substantially
high levels of particulate capsid into the culture supernatant, while virion yield
from cells expressing the C8Fac protein was markedly diminished (Figure
3.14C). In contrast, the C8Fac (Q142C) protein was markedly impaired for
antiviral activity, suggesting that perhaps higher order multimer formation might
be detrimental for the antiviral activity of tetherin (Figure 3.14C). The expression
levels of HIV-1 Gag expression in cell lysates were uniform, indicating that levels
of infection were uniform across all samples (Figure 3.14C). The C8Fac (Q142C)
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protein formed higher order multimers in cell lysates (Figure 3.14C). Importantly,
β-ME treatment did not cause cell lysis and resulted in collapse of C8Fac dimers
and C8Fac (Q142C) oligomers into the monomeric species, indicating that the
concentration of β-ME used in the assay was optimal for reduction of disulphide
bridges (Figure 3.14C). A sizable fraction (~30%) of the C8Fac (Q142C) protein
in cell lysates was found to be resistant to the action of β-ME, and presumably
reflects aggregation of mis-folded protein (Figure 3.14C).
As expected, low levels of particulate capsid protein were released from tetherinnegative cells (Figure 3.14C). In contrast, even lower levels of capsid were
released when C8Fac cells were incubated in buffer alone, and Factor Xa
treatment resulted in the liberation of a substantial amount of capsid (Figure
3.14C). Higher amounts of capsid were released into the supernatant when
C8Fac (Q142C) cells were incubated during the 2h incubation in buffer alone,
which reflects its modest antiviral activity (Figure 3.14C). Notably, there was no
enhancement in the yield of extracellular virions when C8Fac (Q142C) cells were
treated with β-ME (Figure 3.14C). These results suggest that higher order
multimers of tetherin, if extant, do not contribute to HIV-1 restriction.
Unfortunately, repeated attempts to interrogate tetherin species in virions were
not fruitful and the data that we obtained was often difficult to interpret, or was
not always reproducible. Thus, our results did support the notion that tetherin
molecules prefer to adopt the axial configuration during virion entrapment, but we
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were forced to abandon this line of inquiry due to the ambiguity in the
experimental results.

Long heterologous coiled coils as an alternative strategy to determine tetherin
configuration
In an alternate approach, we generated chimeric tetherin proteins in which a
portion of the tetherin ectodomain was substituted by heterologous longer coiled
coils. We reasoned that such a manipulation would increase the separation
between the host cell and viral membranes (ξ) if virions are trapped by axially
configured tetherin molecules (Figure 3.15, top panel). In contrast, ξ would be
unaffected if virions are trapped by dimers or higher order oligomers of tetherin
molecules that are equatorially configured (Figure 3.15, bottom panel). Hence,
we hypothesized that we could use electron microscopy (EM) to visualize
whether any one of the configurations predominates during virion entrapment.
The coiled-coil domains in proteins such as tropomyosin, golgin-84, CASP,
golgin-97, TATA modulatory factor 1 (TMF1), and early endosome antigen 1
(EEA1) are three- to ten-fold greater in length as compared to the ectodomain in
WT tetherin. We appended these coiled-coil sequences C-terminal to the
glycosylation sites and cysteine residues in tetherin, and N-terminal to its GPI
anchor. Care was taken to fuse these coiled-coils in register with the remnants of
the tetherin coiled-coil.
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Figure 3.15. An alternate strategy using hybrid long coiled coils and
electron microscopy to discriminate between axially and equatorially
configured tetherin molecules. (A) Replacement of the coiled-coil domain of
tetherin with a longer coiled-coil would be expected to increase the separation
between the host cell and viral membranes (ξ) in the axial configuration (top
panel). In contrast, ξ would be unaffected when virions are trapped by dimers or
higher order oligomers of tetherin molecules that are equatorially configured
(bottom panel). (B) 293T cells were cotransfected with wild-type (HIV-1 (WT)) or
Vpu-deficient (HIV-1 ∆Vpu) proviral pNL4-3 plasmids along with varying amounts
of wild type tetherin and a variant in which part of the ectodomain is replaced with
the tropomyosin coiled-coil (Tropo). Infectious virion yield was measured by
inoculating HeLa-TZM indicator cells with culture supernatant and is given as the
logarithm to the base 10 of the relative light units (RLU). (C) Western blot
analyses of transfected 293T cell lysates and virions corresponding to the above
panel. All samples were probed with an anti-CA antibody. The numbers at the
bottom represent measurement of CA protein levels in virion pellets (LI-COR).
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Analysis of antiviral activity of the panel of chimeric tetherin proteins revealed
that the tetherin-tropomyosin protein (Tropo) was only modestly proficient at
trapping virions as compared to Tetherin (Figures 3.15A and 3.15B). The other
proteins, which were longer than Tropo, were poorly expressed (data not shown).
We suspected that glycosylation of the long coiled coils, which are normally
destined for the Golgi complex or endosomes, might be attenuating protein
expression. Hence, we generated proteins in which we replaced potentially
glycosylated asparagine residues to serine en masse. Although some of the
proteins were expressed at slightly higher levels, all of them were impaired in
their antiviral activity as compared to Tetherin (data not shown). We also
attempted to improve the antiviral activity of the Tropomyosin-based proteins, by
fusing the tropomyosin coiled-coil domain into the third, fourth, fifth, and sixth Cterminal spacers of C8Fac protein. Such proteins would mimic bacterial virulence
factors wherein stretches of coiled-coil regions are separated by other domains
or unstructured regions (Delahay and Frankel, 2002). However, analysis of the
antiviral activity of these tropomyosin variant revealed that these proteins were
also only modestly capable of inhibiting particulate capsid from being released
into the supernatant (data not shown). Thus, any attempts to increase the length
of the ectodomain came with the penalty of impaired antiviral activity. Most likely,
the differences in length between the coiled-coil domains in the Tropo and
Tetherin proteins would have been too small (~3-fold) to discern any differences
in ξ using EM, and it might have been difficult to discriminate between axially and
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equatorially configured tetherin molecules. Hence, we decided to abandon this
line of investigation.

Summary
In the work discussed above, we employed biochemical assays and engineered
tetherin proteins to demonstrate conclusively that virion tethers are composed of
the tetherin protein itself, and to elucidate the configuration and topology that
tetherin adopts during virion entrapment. We demonstrated that tetherin dimers
adopt an “axial” configuration, in which pairs of transmembrane domains or pairs
of glycosylphosphatidyl inositol anchors are inserted into assembling particles,
while the remaining pair of membrane anchors remains embedded in the infected
cell membrane. We used quantitative western blotting to determine that a few
dozen tetherin dimers are used to trap each virion particle, and that there is ~3-5
fold preference for the insertion of glycosylphosphatidyl inositol anchors rather
than transmembrane domains into tethered virions. We also used biochemical
assays to demonstrate unequivocally that the ESCRT pathway is dispensable for
HIV-1 restriction. In concert, these results demonstrated that axially configured
tetherin homodimers, acting independently of the ESCRT pathway, are directly
responsible for trapping virions at the cell surface.
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Chapter IV Evolutionary origins of tetherin
In this chapter, we employed computational and biochemical analyses to trace
the evolutionary origins of tetherin. How this restriction factor emerged in
mammalian genomes has been utterly mysterious, primarily because there
appear to be no candidate proteins of similar structure or sequence that might
have given rise to tetherin. In this work, we build a case that tetherin arose via
duplication of the neighboring PLVAP/PV1 gene. This project was conducted in
collaboration with Daniel Blanco-Melo, a bioinformatics Ph.D. student in our
laboratory, and the results presented here are being submitted as a research
article. Our findings offer important insights into the remarkable capacity of our
genomes to innovate novel functions from pre-existing genetic raw material using
gene duplication.

Tetherin might have shared a common ancestor with PV1
One question that has captured the imagination of virologists is: how do antiviral
factors evolve? Put another way, what are the mechanisms whereby our
genomes innovate to produce novel functions? As described in the Introduction
(Chapter 1), other restriction factors such as APOBEC3G and SAMHD1 have
likely arisen via duplication of pre-existing genes whose regular cellular functions
were exploited for antiviral activity by minor adaptations. In the case of TRIM5, it
is possible that it arose via duplication and divergence of one of the ~100 family
members of the TRIM family of proteins. In contrast, virtually nothing is known
-124-

about the ancestry of tetherin. In fact, similarity searches for possible ancestors
of tetherin yield no candidate genes of similar sequence and structure. Moreover,
tetherin is dispensable for viability, i.e. it does not perform a developmental or
metabolic role, and is only expressed in most cell types upon stimulation with
interferon. Thus, it is difficult to envisage a scenario wherein tetherin arose from
a gene with a related cellular function. Rather, these observations are compatible
with a simpler model- that tetherin emerged de novo, and purely as an antiviral
gene.
In a seminal monograph, Susumu Ohno proposed that gene duplication creates
new genetic “raw material” that is subjected to the action of evolutionary forces
such as mutation, drift and selection to acquire novel functions (Ohno, 1970).
Clearly, tetherin could not have arisen via retrotransposition, because it contains
introns. Moreover, the other restriction factors probably emerged via gene
duplication and divergence from closely related family members. Thus, we
hypothesized that tetherin might have also evolved via gene duplication, and
initiated a hunt for candidate genes that might have shared a common ancestor
with tetherin. Because duplicated genes tend to lie adjacent to each other in the
genome (Pan and Zhang, 2008), we inspected the genes that flank tetherin in
human chromosome 19, i.e. MVB12A and PLVAP (hereafter referred to as PV1).
We promptly discounted MVB12A because it is a component of the ESCRT-I
complex and it has no predicted transmembrane domain (Morita et al., 2007).
PV1 encodes for a type II integral membrane glycoprotein, whose expression is
restricted to a subset of endothelial cells. It is an essential component of the
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stomatal diaphragms of caveolae and of the diaphragms of fenestrae and
transendothelial channels, and this seems to be its sole cellular function (Stan et
al., 1999).
Remarkably, PV1 appeared to possess most of the topological features that are
peculiar to tetherin, and are essential for its antiviral activity. Both proteins are
type II integral membrane glycoproteins and comprise of a short N-terminal
cytoplasmic tail, a single pass transmembrane domain, and an extracellular
domain which is predominantly coiled-coil (Figure 4.1). Moreover, both proteins
are glycosylated and possess cysteine residues that drive efficient parallel
homodimer formation via disulfide bridges (Figure 4.1). Because PV1 and
tetherin share such overt structural similarity and are located adjacent to each
other, we surmised that tetherin might have shared a common ancestor with
PV1, and that it emerged via gene duplication of that ancestor. Thereafter, the
fortuitous acquisition of a sequence encoding a second membrane anchor (GPI
anchor), might have contributed to the emergence of tetherin.

Phylogenetic analyses of PV1 and tetherin
We first sought to delineate the evolutionary histories of PV1 and tetherin. To that
purpose, we used various platforms such as Ensembl, Uniprot and UCSC
Genome Browser to conduct genome database searches for PV1 and tetherin
genes across phylogeny. It should be noted that the tetherin protein in opossums
and PV1 proteins in birds, reptiles and amphibians were not annotated and were
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Figure 4.1. Structural homology between PV1 and tetherin. Schematic
representation of the tertiary structures of tetherin (top panel) and PV1 (bottom
panel) proteins depicting their shared architectural features. These include Nterminal cytosolic tails, transmembrane domains and extracellular coiled-coil
domains. Both proteins are extensively glycosylated (indicated as blue Y
symbols) and disulfide bridges (indicated by red lines) drive parallel homodimer
formation. The ectodomain of PV1 is three times as long as that of tetherin, and
comprises of two coiled-coil domains interrupted by an unstructured region. The
only differences between the two proteins are a C-terminal GPI modification in
tetherin (indicated as red symbols) and a proline-rich domain in PV1 (indicated
by green lines). Note that crystal structures of the tetherin ectodomain are
available, but none have been solved for PV1.
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identified using orthologous protein queries from related species in BLAT
searches. Our analyses revealed that PV1 is present in the genomes of all
mammals (Figure 4.2A) with homologs in the genomes of birds, frogs and fish;
indicating that it is ~400 MY old (Broughton et al., 2013). Tetherin, on the other
hand, is only present in therian mammals and is absent in egg-laying
monotremes and other animal species (Figure 4.2B), indicating that it is ~147 MY
old (Bininda-Emonds et al., 2007). We were intrigued to notice that tetherin has
duplicated relatively recently in bovids (such as cows) and microbats, leading to
two and four copies of the gene respectively (Figure 4.2B).
The retrieved cDNA sequences for PV1 and tetherin were used to build multiple
alignments using MUSCLE (Edgar, 2004) with manual refinement. These
multiple alignments were used to construct phylogenetic trees using maximum
likelihood methods (Stamatakis, 2006) (Figures 4.2A and 4.2B). The PV1
alignment displays high sequence conservation across mammals, which
suggests that it has evolved under purifying selection (Figure 4.2A). On the other
hand, it is well known that tetherin has evolved under positive selection in
primate species (McNatt et al., 2009) and the longer branch lengths in its
phylogenetic tree illustrates this unusual divergence across species (Figure
4.2B).
To clarify the types of selection pressures that these two genes have been
subjected to during mammalian evolution, we performed codon-based tests of
positive selection on both genes using CODEML (Yang, 1997) under different
nested pairs of models (M0 and M3, M1a and M2a, M7 and M8) (Table 4.1). A
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Figure 4.2. Distribution of PV1 and tetherin across mammals. (A)
Phylogenetic tree of an alignment of PV1 coding sequences in therian mammals.
(B) Phylogenetic tree of an alignment of the TM and coiled-coil domains of
tetherin (codons 22 to133 of human tetherin) in therian mammals. Both
phylogenetic trees were estimated using a maximum likelihood approach
(RaxML). Refer to methods for parameters. One asterisk (*) represents nodes
that are supported in greater than or equal to 80% of the bootstrap replicates.
Two asterisks (**) represents nodes that are supported in greater than or equal to
90% of the bootstrap replicates. Disclaimer: Daniel Blanco-Melo generated the
data for this figure.
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Table 4.1. Likelihood ratio test on nested models of variable ω ratios
among sites for PV1 and Tetherin genes. Likelihood ratio tests on nested
models of variable ω ratios among sites were performed to determine positions
with dN/dS values > 1 (positive selection). Neutral models of selection (M0, M1,
M7) were compared to models that allow variation on dN/dS among sites (M3) or
selection models (M2, M8). P-values were calculated using a chi square
distribution. DOF: degrees of freedom. PSS: number of positive selection sites
(Naïve Empirical Bayes) with posterior probabilities > 0.95. NS: Non-significant.
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ratio of non-synonymous substitutions/non-synonymous sites (dN) versus
synonymous substitutions/synonymous sites (dS), i.e. dN/dS, greater than 1
indicates that the sequence is diverging away from the ancestral state, and is
evolving under positive selection. On the other hand, a dN/dS ratio lesser than 1
indicates that natural selection has conserved the ancestral state and that the
sequence is evolving under purifying selection. Our analyses support previous
findings that tetherin has evolved under positive selection across primates, and
extend its time span to all therian mammals (M1 vs. M2: p-value < 0.002; M7 vs.
M8: p-value <<0.001) (Table 4.1). We also showed that PV1 has evolved under
purifying selection in therian mammals (dN/dS < 1). Interestingly, the M0 vs. M3
likelihood ratio test suggests that different portions of the PV1 sequence have
been shaped by different selection pressures (all with dN/dS < 1). It is difficult to
speculate the nature of these evolutionary forces, given that PV1 performs a
housekeeping function. From these analyses, we conclude that tetherin probably
originated between the times that monotremes and marsupials diverged away
from mammals (~166-147 MYA). We speculate that the opposing selection
pressures (i.e. positive versus purifying selection) might have been responsible
for the neofunctionalization of one of the PV1 paralogs to tetherin, and its
subsequent divergence from PV1.
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Evidence that the antiviral activity of tetherin arose early during its evolution
It is possible that tetherin was subjected to viral selection pressures soon after its
birth. Thus, we wondered if its ability to trap enveloped virions was ancient or had
arisen recently in its evolutionary history. To that end, we assessed the antiviral
activity of the tetherin protein in Tasmanian devils, which is the most divergent
protein from the human variant (Figure 4.3A). Sequence comparison tools
revealed that the identity between the two proteins is 31% and the similarity is
55% (Figure 4.3A).
We analyzed antiviral activity by transfecting 293T cells with either a HIV-1
proviral plasmid (HIV-1(WT)) or its Vpu-deficient counterpart (HIV-1(∆Vpu)),
along with various amounts of plasmids encoding human and devil tetherin
proteins. As expected, human tetherin potently inhibited the release of HIV-1
(∆Vpu) in a dose-dependent manner, while only marginally affecting the release
of HIV-1 (WT) (Figures 4.3B and 4.3C). The devil tetherin protein potently
inhibited the release of extracellular HIV-1 particles, and its antiviral activity was
virtually indistinguishable from that of human tetherin (Figures 4.3B and 4.3C).
Inhibition occurred without detrimental effects on Gag protein expression (Figure
4.3C). Predictably, devil tetherin was not antagonized by HIV-1 Vpu (Figure
4.3B), which has evolved specifically to antagonize human tetherin (Neil et al.,
2006; Van Damme et al., 2008). Overall, it appears that tetherin proteins as
widely divergent as those found in marsupials, possess antiviral activity against
enveloped viruses. These results suggest that the ability to trap virions was
acquired relatively early during the evolutionary history of tetherin.
-134-

Figure 4.3. Tetherin acquired antiviral activity early during its evolution. (A)
A sequence alignment of human and Tasmanian Devil tetherin proteins
generated using the Emboss Water Pairwise Sequence Alignment tool. The
conserved residues (indicated as vertical lines) are shaded in blue for
convenience. A colon (:) indicates conservation between strongly similar
residues, while a period (.) indicates conservation between weakly similar
residues. (B) 293T cells were cotransfected with WT (empty circles) or Vpudeficient (filled circles) proviral pNL4-3 plasmids along with varying amounts of
human or Tasmanian Devil tetherin proteins. Infectious virion yield was
measured by inoculating HeLa-TZM indicator cells with culture supernatant and
is given as the logarithm to the base 10 of the relative light units (RLU). (C)
Western blot analyses of transfected 293T cell lysates and virions corresponding
to the Vpu-deficient samples in (B). All samples were probed with an anti-CA
antibody.
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PV1 and tetherin share no sequence homology
In principle, the gold standard to prove unequivocally that two genes share a
common ancestor is to detect significant sequence homology between them at
either the nucleotide or the amino acid levels. However, current global and local
sequence alignment methods fail to detect any significant sequence similarity
between PV1 and tetherin. Among PV1 sequences, the similarity between introns
and other presumed neutrally evolving sites diminishes from primates to rodents
and almost disappears from primates to marsupials and monotremes (Figure
4.4). Note that the non-eutherian mammals (i.e. monotremes and marsupials)
diverged from eutherian mammals ~101 MYA (Bininda-Emonds et al., 2007;
Margulies et al., 2005; Nikolaev et al., 2007). A key question is- should we expect
to observe sequence homology, given the time at which PV1 and tetherin
putatively diverged? It might be difficult to observe sequence homology between
tetherin and PV1 due to opposite selection forces on the two genes, resulting in
the accelerated evolution and divergence of the tetherin sequence away from
PV1, and the amount of time involved since the duplication. Thus, it is possible
that any sequence homology has been lost with the proviso that structural
similarity still persists, to preserve its antiviral activity.
In order to test this possibility, we reconstructed ancestral PV1 sequences and
simulated their evolution in silico under tetherin-like conditions, to ultimately
assess the sequence similarity between the simulated sequences and
contemporary PV1 sequences. We reconstructed ancestral PV1 sequences for
the common ancestor of all mammals (166.2 MYA) and for the common ancestor
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Figure 4.4. No significant similarity in introns and other presumed neutrally
evolving sequences across widely divergent PV1 genes. A global sequence
alignment of PV1 genes from primates to monotremes was generated using the
VISTA visualization module for comparative genomics. The graph shows the
percentage of conservation between the two organisms at any given coordinate.
The pink regions correspond to noncoding sequences, the dark blue regions are
exons, and the light-blue regions are the untranslated regions. The human PV1
gene serves as the reference sequence for the alignment.
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of therian mammals (147.7 MYA) using maximum likelihood methods (Yang,
1997). We allowed the mammalian ancestral PV1 sequences to evolve at typical
mammalian neutral substitution rates (i.e. dN/dS = 1), for a time span of 18.5 MY
(i.e. the time span wherein the putative duplication might have occurred). We
used the EvolveAGene 3 software (Hall, 2008), with no selection against indels,
to produce 100 fully coding simulated sequences. These sequences were used
as input for the Seq-Gen software (Rambaut and Grassly, 1997) to simulate
evolution under tetherin-like conditions for the rest of the mammalian tree.
Parameters for Seq-Gen were estimated by ModelTest (Posada and Crandall,
1998) using the Bayesian Information Criterion (BIC) likelihood test. For each
neutral substitution rate, 100 replicates for each neutrally evolved PV1 sequence
were produced, and the simulated 10,000 mouse, dog and human sequences
were compared to contemporary mouse, dog and human PV1 respectively, using
tblastn. Additionally, Seq-Gen was used to evolve therian ancestral PV1 under
tetherin-like parameters with 10,000 replicates. The simulated mouse, dog and
human sequences were compared to mouse, dog and human PV1 proteins
respectively using BLAST. Note that a commonly used measure of sequence
similarity is the expectation value (e-value). Essentially, an e-value is a
parameter that describes the number of hits one can expect to see by chance
when searching a database of a particular size (Koonin and Galperin, 2003). For
example, an E value of 1 assigned to a hit can be interpreted as meaning that in
a database of the current size one might expect to see 1 match with a similar
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score simply by chance. Thus, the closer the e-value is to zero, the more
significant is the match between query and hit (Koonin and Galperin, 2003).
Overall, the majority of the BLAST hits had ~30 percent identity; however the
quality of the hits varied significantly depending on the neutral substitution rate
and the PV1 sequence used as query (Figure 4.5). Without 18.5 MY of neutral
evolution, BLAST was able to find significant high scoring hits with nearly all of
the 10,000 simulated sequences using human and dog PV1 protein sequences
as queries (Figure 4.5A). In contrast, using mouse PV1 as a query, BLAST was
able to find significant hits only with 28% of the sequences (2,853 of 10,000),
with the majority of them having e-values ≤ 0.001 (Figure 4.5A). This scenario
was intensified if the simulated sequences were allowed to evolve under neutral
selection prior to the tetherin-like conditions. Significant BLAST hits with mouse
PV1 were found only in a small fraction of sequences, from 2.8% using a neutral
substitution rate of 1.5 x 10-9 substitutions/ site/year, to 0.8% using a neutral
substitution rate of 5 x 10-9 substitutions/site/year (Figures 4.5B-4.5D). Using dog
and human PV1 as queries, the majority of the BLAST hits were found to have
an e-value ≤ 0.01 irrespective of the neutral substitution rate used (Figures 4.5B4.5D). Notably, there is always a subset of simulated sequences where BLAST
fails to find sequence homology to contemporary PV1 sequences. The frequency
of the “non-homologous” sequences varies from 45% and 31%, using 1.5 x 10-9
substitutions/site/year, to 71% and 64%, using 5 x 10-9 substitutions/site/year, in
dog and human comparisons, respectively (Figures 4.5B-4.5D). Additionally, for
those sequences where BLAST was able to detect sequence homology, a
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Figure 4.5. In silico evolution of tetherin from ancestral PV1 sequences.
Frequency histograms of the significance of tBLASTn hits comparing
contemporary PV1 protein sequences and in silico simulated “tetherin”
sequences. The ancestral mammalian PV1 sequence was evolved under distinct
neutral substitution rates for a period of 18.5 MY, i.e. the time interval in which
tetherin is projected to have emerged (100 replicates): (A) 0, (B) 1.5x10-9, (C)
3x10-9 and (D) 5x10-9 substitutions/site/year. Each sequence was then evolved
under parameters that best fit the tetherin alignment for the remaining
mammalian lineages (100 replicates). Simulated mouse, human and dog
sequences were compared using tBLASTn to contemporary mouse (blue),
human (green) and dog (red) PV1 protein sequences. X-axis intervals: 0.001 (evalue = 0.001), 0.01 (0.001 < e-value = 0.01), 0.1 (0.01 < e-value = 0.1), 1 (0.1 <
e-value = 1), 10 (1 < e-value = 10), 100 (10 < e-value = 100) and NH (No Hits,
fraction of simulated sequences with no blast hits). Disclaimer: Daniel BlancoMelo generated the data for this figure.
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substantial fraction corresponds to non-significant poorly scoring hits. The large
proportion of sequences lacking homology with mouse PV1 within any of the
simulated data sets can be explained by its high degree of divergence and the
high neutral substitution rate of mice (4.5 x 10-9 substitutions/site/year). Thus, it is
clear that the introduction of neutral evolution immediately after the hypothetical
PV1 duplication was the main source of sequence divergence. This observation
is also supported by the lack of sequence homology between ancestral PV1
sequences and ancestral tetherin sequences (data not shown). We conclude that
it is possible to evolve sequences from an ancestral PV1 sequence that bear no
significant sequence homology to contemporary PV1, after simulating the
evolutionary processes that might have contributed to the emergence of tetherin.
Thus, PV1 and tetherin might share common ancestry, even though they share
no significant sequence homology.

PV1 can be endowed with antiviral activity upon acquisition of a second anchor
Both membrane anchors of tetherin are indispensable for trapping virions at the
cell surface (Perez-Caballero et al., 2009). Because the only glaring difference
between the overall architectures of PV1 and tetherin is the second anchor in
tetherin, we reasoned that the relatively trivial manipulation of appending the Cterminus of PV1 with the tetherin GPI anchor would be sufficient to endow it with
the ability to trap virions. The underlying rationale is that if two proteins share a
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common structure, then the proteins might be expected to perform the same
function.
Analysis of the antiviral activity of the panel of PV1 proteins revealed that the
PV1-GPI protein is at least as potent as artificial tetherin, which is an entirely
synthetic protein that bears no sequence homology to human tetherin, but
preserves its overall architecture (Perez-Caballero et al., 2009) (Figures 4.6A
and 4.6B). Moreover, the PV1-GPI protein is only moderately impaired as
compared to human tetherin (Figures 4.6A and 4.6B). Note that the endogenous
levels of PV1 are insufficient for trapping virions (Figure 4.6B). Interestingly, the
PV1 protein itself has modest antiviral activity (Figures 4.6A and 4.6B), perhaps
due to its propensity to dimerize and organize itself into ring-like structures via Cterminal tail-tail interactions (Stan, 2005). We also wondered if we could further
improve the antiviral activity of the chimeric PV1-GPI protein by truncating the Nterminal cytoplasmic tail. Such a protein (hereafter referred to as PV1-DelCTGPI) cannot be internalized by the cellular endocytic machinery, and is expected
to freely diffuse into sites of particle assembly. However, truncation of the
cytoplasmic tail had no effect on antiviral activity (PV1-DelCT-GPI; Figures 4.6A
and 4.6B). Note that the PV1 and tetherin proteins are heterogeneously
glycosylated, and because the cells were lysed in non-reducing buffer, all
proteins migrated primarily as a smear of dimeric species (Figure 4.6B). We
conclude that PV1 performs the biological function of tetherin when it is
engineered to encode a C-terminal GPI anchor.
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Figure 4.6. Antiviral activity of the panel of modified PV1 proteins. (A) 293T
cells were cotransfected with Vpu-deficient proviral pNL4-3 plasmid (HIV-1 ∆Vpu)
along with varying amounts of the indicated tetherin and modified PV1 proteins.
Infectious virion yield was measured by inoculating HeLa-TZM indicator cells with
culture supernatant and is given as the logarithm to the base 10 of the relative
light units (RLU). (B) Western blot analyses of transfected 293T cell lysates and
virions corresponding to the above panel. The cell lysates were probed with antiCA, anti-HA, and anti-PV1 antibodies, and the virions were probed with anti-CA
antibody. The numbers at the bottom represent measurement of CA protein
levels in virions (LI-COR).
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Genomic distribution of PV1/tetherin-like proteins
The hypothesis that PV1 and tetherin might share a common ancestor stems in
part from the observation that they share a relatively unusual overall architecture.
To quantify the abundance of this architecture in animal genomes, we searched
for human and mouse proteins that share structural features with PV1. We
downloaded all 105,281 human and 54,447 mouse annotated protein sequences
from Ensembl (Release 71) (Flicek et al., 2013) using BioMart. Proteins were
then selected using the following criteria: (i) presence of one transmembrane
domain (TMD) using tmhmm 2.0 (probability > 0.5) (Krogh et al., 2001), and (ii)
coiled-coil domains of various lengths C-terminal to the TMD using COILS
(Lupas et al., 1991) (probability > 0.5). We identified 211 human and 175 mouse
PV1/tetherin proteins with a minimal coiled-coil domain of 21 amino acid residues
and subsequently determined which of those genes lay adjacent to each other in
the genome, and bore significant homology to each other.
It is noteworthy that 30% of duplicated genes (i.e. those genes with significant
sequence homology) are located adjacent to each other and are in the same
orientation (Pan and Zhang, 2008). Interestingly, 7 out of 10 PV1/tetherin-like
gene pairs that are adjacent to each other in the human genome and that are in
the same orientation, share significant homology, and thus likely arose via gene
duplication. The exceptions are CLEC4M and EVI5L, BCAP29 and SLC26A4,
and PV1 and tetherin. Notably, PV1 and tetherin is the only pair that conforms to
a more stringent criterion, i.e. the coiled-coil domains in both proteins are greater
than 28 amino acid residues. In contrast, the only PV1/tetherin-like genes that
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are adjacent to each other in the human genome, but that are in the reverse
orientation (EVC and EVC2), share no significant homology. This is intuitive
because adjacent genes in the reverse orientation are not expected to have
evolved via gene duplication. In the mouse genome, of a total of 6 PV1/tetherinlike gene pairs that lie adjacent to each other and that are in the same
orientation, PV1 and tetherin are the only genes that share no sequence
homology. To summarize, an architecture N-TMD-Coiled-coil-C is quite rare in
the human and mouse genomes, and accounts for only ~0.3% of all annotated
proteins. It is rarer still to find adjacent genes that bear this architecture.
Moreover, the majority of these genes that are in the same orientation, share
significant homology, and hence likely arose via gene duplication. These results
indicate that it is quite possible that tetherin arose from PV1, although the two
genes share no significant sequence homology.

Some, but not all, PV1/Tetherin-like proteins can be endowed with antiviral
activity
To test if PV1/tetherin-like proteins can be engineered to trap virions, we selected
candidates that have at least one cysteine residue in their ectodomain, and
whose coiled-coil domains are similar in length or exceed that of human and
mouse tetherin proteins. Next, using the Uniprot database (Uniprot, 2014), we
pruned this list further using two criteria. First, the proteins should reside at the
cell surface. Second, they should form homodimers efficiently. Two candidate
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proteins (i.e. CD72 and CLEC1A) conformed to the above constraints and were
selected for structure-function analyses as earlier.
Interestingly, the CD72 protein had a modest intrinsic capacity to inhibit the
release of extracellular HIV-1 particles, whereas CLEC1A was almost completely
inactive (Figures 4.7A and 4.7B). Unlike PV1, the addition of a second
membrane anchor did not stimulate the antiviral activity of these proteins
(Figures 4.7A and 4.7B). In contrast, truncation of the N-terminal cytoplasmic tail
substantially improved antiviral activity, and a CD72 protein with both
manipulations was as potent as artificial tetherin at trapping virions (CD72DelCT-HA-GPI, Figures 4.7A and 4.7B). Taken together, it appears that
straightforward alterations endow, some, but not all, PV1/tetherin-like proteins
with the intrinsic ability to trap virions.

Model for the genesis of tetherin via duplication of an ancestral PV1 gene
To reconstruct the events that lead to the genesis of tetherin, we analyzed the
organization of genes in the PV1 locus across the phylogenetic tree. In
eutherians, the PV1 and tetherin genes lie adjacent to each other, and their
neighbours form a perfect synteny block (Figure 4.8). In contrast, PV1 and
tetherin are separated by ~31 MB in marsupials such as the opossum, and
tetherin lies immediately adjacent to CILP2 and YJEFN3 (Figure 4.8). Note that
the latter two genes are separated from tetherin in eutherians (Figure 4.8). Our
efforts to reconstruct the PV1 locus in birds and monotremes (where tetherin is
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Figure 4.7. Antiviral activity of the panel of PV1/tetherin-like proteins. (A)
293T cells were cotransfected with Vpu-deficient proviral pNL4-3 plasmid (HIV-1
∆Vpu) along with varying amounts of the modified CD72 and CLEC1A proteins.
Infectious virion yield was measured by inoculating HeLa-TZM indicator cells with
culture supernatant and is given as the logarithm to the base 10 of the relative
light units (RLU). (B) Western blot analyses of transfected 293T cell lysates and
virions corresponding to the above panel. The cell lysates were probed with antiCA and anti-HA antibodies. Virions were probed with anti-CA antibody.
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Figure 4.8. Model for the genesis of tetherin. Inspection of the genes that flank
PV1 in amphibians (frog) and reptiles (turtle) yields a syntenic gene block that is
presumably also maintained in monotremes (platypus). Tetherin proteins are only
found in marsupials and eutherian mammals. The duplication of PV1 is estimated
to have taken place between the times that monotremes and marsupials
diverged from mammals (~166-147 MYA). Tetherin evolved under neutral
selection for a short while, acquired a GPI anchor, became neofunctionalized and
fixed. Its antiviral activity was then shaped by interactions with past viruses.
Clade-specific insertions interrupted the ancestral gene configuration in therian
mammals, leading to the separation of PV1 and tetherin in marsupials such as
opossums. Importantly, tetherin and PV1 continue to lie adjacent to each other in
the rest of the mammals, although they are separated from CILP2 and YJEFN3.
-154-

absent) were impaired because their genomes are either poorly annotated or
have not been assembled completely. However, we observed that PV1 is
contiguous with CILP2 and YJEFN3 in amphibians (frog) and reptiles (turtle)
(Figure 4.8). Importantly, GTPBP3 lies immediately adjacent to PV1 in all animal
species (Figure 4.8). Thus, we speculate that the ancestral configuration of the
PV1 locus might have been GTPBP3, PV1, CILP2, YJEFN3 (Figure 4.8). One
could envisage a scenario wherein a duplication of PV1 led to the emergence of
tetherin at some point between the times that the monotreme and marsupial
lineages diverged from the mammalian lineage (i.e. ~166-147 MYA) (Figure 4.8).
Thereafter, lineage-specific insertions and deletions could have resulted in
tetherin either segregating with CILP2 and YJEFN3 in marsupials or with
GTPBP3 and PV1 in eutherians (Figure 4.8).

Summary
The evolutionary origins of tetherin are obscure. In this work, we employed
computational and biochemical approaches to build a case that tetherin arose via
duplication of the neighboring PV1 gene. The PV1 and tetherin genes are located
adjacent to each other in eutherian mammals and encode proteins with a shared
and relatively unusual overall architecture. Phylogenetic analyses provided
evidence that tetherin is ~147 MY old and that it has evolved under positive
selection. Conversely, PV1 is ~400 MY old and has evolved under purifying
selection in therian mammals. Using biochemical assays, we demonstrated that
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PV1 can be endowed with antiviral activity against HIV-1 when it is engineered to
encode a C-terminal GPI anchor. Although we did not detect any sequence
homology between PV1 and tetherin, in silico evolution experiments indicated
that it is possible to evolve sequences from an ancestral PV1 sequence that bear
no significant homology to contemporary PV1, after simulating the evolutionary
processes that contributed to the emergence of tetherin. We found that genes
encoding proteins with PV1/tetherin-like architecture are quite rare in the human
and mouse genomes, and that the majority of these genes that are adjacent to
each other likely arose via gene duplication. Moreover, some, but not all,
PV1/tetherin-like proteins have the intrinsic ability to trap virions, when appended
with a GPI anchor. Finally, we analyzed the organization of genes in the PV1
locus from amphibians to eutherian mammals and identified an ancestral synteny
block that supports a model in which tetherin arose from a PV1 duplication that
occurred between the times that monotremes and marsupials diverged from
other mammals (~166-147 MYA). Cumulatively, these findings suggest that
tetherin arose by gene duplication of PV1 and highlight the remarkable capacity
of our genomes to innovate antiviral factors from pre-existing genetic raw
material.

-156-

Chapter V Discussion
It is only recently that we have come to appreciate that there exists an arsenal of
proteins that constitutes the first line of resistance against viral infections
(Bieniasz, 2004). These defenses are either constitutively active or are mobilized
upon viral infection, and directly inhibit viral replication using intriguing and
unanticipated mechanisms of action. As antiviral host genes continue to be
identified, we have also come to appreciate how their histories are shaped by
pathogens. In this body of work, we strived to dissect the molecular mechanisms
that underpin the antiviral activity of one such protein, tetherin. In parallel, we
also aimed to chart the evolutionary course of this protein, and to arrive at a
molecular explanation as to how it might have acquired its antiviral activity.
We began our investigation by formulating a biochemical approach to probe
tetherin molecules that have infiltrated virions at the cell surface, with the goal of
elucidating the configurations adopted by tetherin during virion entrapment. This
approach was based on two previous findings. First, a non-specific protease,
subtilisin A, could be used to liberate tethered particles from the infected cell’s
surface (Neil et al., 2006; Neil et al., 2007). Second, the primary sequence of
tetherin can be drastically altered whilst retaining biological activity (PerezCaballero et al., 2009). Thus, we employed the site specific protease Factor Xa
to liberate virions trapped by tetherin molecules that were engineered to include
its cleavage site. This manipulation gave the approach tight specificity and
enabled the unequivocal demonstration that the tetherin protein itself is an
essential component of virion tethers. Moreover, the use of a site specific
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protease to release tethered virions from cell surfaces enabled the preservation
of epitope tags inserted into the tetherin ectodomain, allowing us to infer the
organization of tetherin molecules in virion tethers. We could use a double
epitope-tagged version of tetherin, as well as single epitope-tagged versions to
analyze the incorporation of both N- and C-terminal proteolytic fragments into
virions,

and

thereby

determine

tetherin

configuration.

Additionally,

we

constructed a protein standard and performed quantitative western blotting to
estimate the numbers of tetherin dimers in each orientation that are associated
with trapped virions.
Because virions were efficiently liberated by Factor Xa treatment of N5Fac or
C8Fac

expressing cells,

our data effectively exclude

the ‘‘equatorial’’

configuration shown in Figure 3.1B, as cleavage of the tetherin peptide backbone
in this context would leave intact the majority of the bonds anchoring the virion to
the cell surface. Moreover, the fact that tetherin fragments found in virions
liberated by Factor Xa were exclusively disulphide linked homodimers also
constitutes strong evidence disfavoring this model. While our data do not
completely discount the possibility that tetherin multimers adopt the equatorial
configuration, with virions becoming trapped via hypothetical non-covalent dimerdimer interactions (Figure 3.1C), this scenario appears unlikely for two reasons.
First, such a configuration would not be expected to result in virion release upon
Factor Xa cleavage, because dimer-dimer interactions would not be expected to
be perturbed, particularly since the Factor Xa cleavage site is placed within a
foreign spacer sequence whose insertion does not itself perturb tetherin function.
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Second, the scenario envisaged in Figure 3.1C would result in precisely equal
numbers of tetherin N- and C termini being placed in tethered virions. We found
that there were modestly, but clearly, more tetherin C-termini than N-termini in
virions, arguing that tetherin N- and C-termini partition separately into virion and
cell membranes. In summary, our experiments indicated that tetherin
homodimers adopt an axial configuration in their functional state, with a
preference for the insertion of their GPI anchored C-termini into virions during
their entrapment at the surface of infected cells. Quantitative analysis indicated
that an average of 80 to 400 tetherin dimers (depending on how many CA
molecules are assumed to be present in each virion) associated with each
tethered particle. Our findings do not discount the discount the possibility that
higher order tetherin multimers, e.g. tetramers, might contribute to tethering, but
if such complexes do exist, then they must involve non-covalent interactions
between axially configured tetherin molecules and be arranged in such a way
that all N-termini and in one membrane (be it virion envelope or cell membrane)
and all C-termini are in the opposing membrane.
To fortify our claim that axially configured tetherin homodimers are responsible
for trapping virions, we adopted two approaches to further investigate the role for
the configurations depicted in Figures 3.1B and 3.1C. First, we attempted to
generate a longer chimeric tetherin molecule, because such a protein might have
allowed us to visualize the increase in separation between cell and viral
membranes when virions are trapped by axially configured as opposed to
equatorially configured molecules. However, we were unable to design a longer
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protein that would also recapitulate the antiviral activity of tetherin. One possible
reason for this is that the length of the ectodomain might have been optimized by
evolutionary forces for virion entrapment, and that artificially lengthening it might
compromise antiviral activity. In our second approach, we compared the yield of
β-mercaptoethanol-liberated virions from cell lines expressing a cysteine mutant
that had the propensity to form higher order multimers and a non-crosslinkable
mutant. Because there was no further release of virions, it does suggest that
higher order multimers of tetherin do not contribute to the retention of virions.
However, our inability to probe virions for the identity of the associated tetherin
species led us to abandon this line of questioning.
Previous studies have not resolved the configuration adopted by tetherin as it
engages in virion entrapment. For example, conflicting results have been
obtained in studies where the release of virions was attempted by cleavage of
the tetherin GPI anchor using phosphatidyl-inositol-specific phospholipase C (PIPLC). In one study, the efficiency of virion release induced by PI-PLC treatment
was poor (20% compared to subtilisin) (Lehmann et al., 2011), while other
studies indicated that PI-PLC treatment fails to liberate any virions (Andrew et al.,
2011; Fitzpatrick et al., 2010). Second, the failure of reducing agents to release
virions would tend to suggest that the equatorial model shown in Figure 1B is
incorrect (Fitzpatrick et al., 2010). However, this argument is somewhat
confounded by the fact that tetherin molecules are twisted around each other in a
dimer, and so breaking the disulphide bonds in an already-formed tether would
not necessarily be expected to cause virion release.
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One caveat of our assay is that some tetherin dimers might infiltrate particles and
yet be uninvolved in restriction. Thus, it is possible that the number of tetherin
molecules that we measured to be associated with a virion might be greater than
the number of molecules actually involved in virion entrapment. Indeed, previous
studies have shown that low levels of complete tetherin molecules can be found
in the small number of virions that are released from tetherin-positive cells
(Fitzpatrick et al., 2010). However, to be uninvolved in restriction would require
that both tetherin N- and C-termini were embedded in virions. If the numbers of
tetherin dimers that were inserted into virions in this way was in excess of the
numbers of tetherin dimers involved in tethering, with N- and C-termini partitioned
separately into virion and cell membranes, then there would be little or no
difference in the number of tetherin N- and C-termini found in virions. The fact
that we do indeed observe a 3-to 5-fold excess C-termini in tethered virions,
argues strongly that most of the tetherin molecules (at least 65–80%) that are
tethered-virion associated, have their N- and C-termini separately partitioned into
virion and cell membranes. Thus, most tetherin molecules must be in the axial
configuration with only their C-termini embedded in virions.
Our estimates of the number of tetherin molecules that are associated with
tethered virions are several-fold higher than those obtained using superresolution microscopy approaches (i.e. 4–7 dimers per virion) (Lehmann et al.,
2011). At least three factors could account for this discrepancy. First, the
microscopy studies use a tetherin-mEosFP fusion protein, that includes a bulky
230 amino acid (~26 kDa) protein at its N-terminus, appended to the otherwise
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short (21 amino acid) native tetherin cytoplasmic tail. This could very easily
reduce the numbers of tetherin molecules that associate with virions. Second, the
estimates made in the microscopy studies correspond to groups of tetherin
molecules present at the same location as clusters of Gag molecules that may
not represent completely assembled virions. Thus, microscopy studies cannot
determine whether the imaged tetherin molecules are in the act of restriction.
Conversely, our estimates are based on bona fide tethered virions that are
recovered from cells by specific cleavage of the tether. Finally, the cell lines that
we used to derive our estimates modestly overexpressed tetherin (1.5- to 3- fold)
as compared to HeLa cells, which might have slightly elevated the numbers of
tetherin molecules that were associated with virions. In previous studies
(Lehmann et al., 2011), transfected HeLa cells were used, and the levels of
tetherin mEosFP relative to preexisting endogenous tetherin, or the total
(endogenous plus exogenous) levels of tetherin expression were not determined,
which could lead to underestimates or overestimates of tetherin association with
tethered virions.
Given that virions are trapped not only at the cell surface, but are also linked to
each other, it should be expected that both tetherin N-and C-termini would be
found in virions. Most likely, the appearance of virions tethered to each other
results from the assembly of a virion at a location on the plasma membrane
already occupied by a tethered particle. This being so, our finding of a 3- to 5-fold
preference for the insertion of C-termini rather than N-termini into virion
membranes may represent an underestimate of the true preference. If this is the
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case, then one might expect that the apparent preference for the insertion of Ctermini into virions would become diluted over time as virions accumulate at the
cell surface and the likelihood of a virion assembling at a site already occupied
by a tethered virion increases. However, we did not observe such a trend, and
thus it remains unclear whether the 3- to 5-fold preference for C-terminus
insertion into virions is an accurate number, or an underestimate resulting from
virion accumulation.
The biophysical mechanism underpinning the apparent preference for the
insertion of GPI-anchored C-termini over TM domain-anchored N-termini into
virions is unclear at present. Although it is not the predominant scenario, the
tetherin N-terminal domain is clearly capable of being incorporated into virions.
Indeed, a tetherin molecule lacking the GPI anchor is efficiently incorporated into
released virions (Perez-Caballero et al., 2009). Moreover, it is the N- terminus
that is targeted by Vpu to block tetherin incorporation into virions (McNatt et al.,
2009; Perez-Caballero et al., 2009). Perhaps the tetherin N-terminal domain acts
as a sensor of membrane curvature, driving localization to assembly sites, but
the GPI anchor diffuses more freely into virion membranes. Consistent with this
idea, recent work indeed indicates that tetherin colocalizes better with HIV-1 Gag
proteins that cause membrane curvature than those which do not (Grover et al.,
2013). Incidentally, this ability is not reliant on the ESCRT pathway, as illustrated
by our finding that tetherin is proficient at trapping virions that assemble
independent of the ESCRT pathway. Using conventional microscopy, a previous
study noted that the ability of tetherin to be recruited to late domain mutants of
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Gag is severely impaired (Grover et al., 2013). Certainly, the antiviral activity of
tetherin is compromised when it is localized incorrectly (McNatt et al., 2013).
However, assembly of a late domain mutant is arrested before completion,
whereas tetherin traps mature, nascent particles that have budded from the
infected cell membrane. Thus, the claims made by previous studies must be
treated with circumspection because the use of late domain mutants to test for
tetherin function is confounded by the fact that late domain mutants arrest
assembly at an earlier stage than when tetherin traps virions.
There is potential biological utility in preferentially inserting GPI anchored tetherin
C-termini rather than N-termini into virions. In such a scenario, the tetherin Nterminus remains available to the cytoplasm of the infected cell, from where it
may execute important functions. For instance, virions trapped at the cell surface
are internalized and degraded in lysosomes (Harila et al., 2006; Neil et al., 2006).
Moreover, human tetherin appears capable of initiating signaling cascades,
particularly when it is engaged in tethering, and is certainly in pole position to act
as a virion sensor (Cocka and Bates, 2012; Galao et al., 2012; Tokarev et al.,
2012). As such, the need to interact with the endocytic machinery and/or initiate
signaling might favor a scenario in which tetherin dimers are oriented with their
N-termini in the infected cell and their C-termini in the virion membrane. Thus,
the mechanistic principles that we have elucidated are also consistent with the
auxiliary functions of tetherin such as endocytosis and signaling.
In addition to these efforts, we also endeavored to trace the ancestry of tetherin.
The evidence that we gathered built a provocative case for its emergence via
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gene duplication of PV1, followed by neofunctionalization and selection. A
number of circumstantial lines of evidence supported this hypothesis. First, PV1
and tetherin share a relatively unusual overall architecture. Second, phylogenetic
analyses demonstrate that tetherin is only present in therian mammals, whilst
PV1 is far more ancient. Third, appending the C-terminus of PV1 with a second
membrane anchor confers antiviral activity against HIV-1. Fourth, both proteins
are located adjacent to each other in eutherian chromosomes, indicative of gene
duplication. Additionally, reconstruction of the PV1 locus across species yields a
putative ancestral configuration that supports a model for the events that led to
the genesis of tetherin.
We were unable to find a tetherin gene in the monotreme genome, which
engendered the reasonable hypothesis, that tetherin emerged after monotremes
diverged away from therian mammals (i.e. ~166-147 MYA). PV1, on the other
hand, is ~400 MY old and our analyses confirmed that it has evolved under
purifying selection in therian mammals (Figure 4.2A and Table 4.1). In essence,
PV1 and tetherin seem to follow a paradigm of gene duplication wherein one of
the paralogs is free to diverge and acquires a novel function (Figure 5.1). We
posit that the duplication of PV1 yielded two paralogs; one continued to perform
the ancestral function of PV1 in endothelial cells, whilst the other became
redundant and diverged under neutral selection (Figure 5.1). We speculate that
this paralog might have acquired a novel antiviral function by fortuitously gaining
a GPI anchor via mutation and was thereafter optimized by a variety of selection
pressures, likely of viral origin (Figure 5.1). Subsequently, it became fixed,
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Figure 5.1. Evolutionary processes that might have contributed to the
genesis of tetherin. PV1 has evolved under purifying selection in mammals, and
upon gene duplication, one of the paralogs continued to perform its cellular
function. The other paralog probably evolved under neutral selection and
acquired mutations that led to the acquisition of a GPI anchor, thus leading to the
birth of tetherin. Subsequently, tetherin acquired antiviral activity (i.e. it was
neofunctionalized) and it evolved in competition with viruses soon after its
emergence. Eventually, it was fixed in the population and evolved under positive
selection in therian mammals.
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leading to the emergence of tetherin (Figure 5.1). As a consequence of its
genetic conflict with enveloped viruses, tetherin then evolved under positive
selection (Figure 5.1). The striking observation that the tetherin protein in
Tasmanian devils potently traps HIV-1 virions (Figures 4.3B and 4.3C) bolsters
the view that tetherin evolved in competition with viral pathogens soon after its
birth.
It is reasonable to expect sequence homology if two proteins are related. In spite
of our best efforts, we could not detect any significant homology at the nucleotide
or amino acid levels by employing current sequence alignment methods (Figure
4.4). We concede that this observation weakens our proposition that tetherin
might have shared an ancestor with PV1. Nevertheless, it is encouraging that we
were able to evolve sequences that bore no significant homology with
contemporary PV1 sequences in our in silico evolution experiments (Figure 4.5).
It is important to note that the events that occurred between the times when the
monotremes and marsupials diverged from the rest of the mammals were
responsible for rapid sequence divergence of early tetherin. We conducted our
analysis under neutral evolution, which seemed to be the best approximation of
those events. We observed that more than 50% of the simulated data bore no
homology to dog PV1 or human PV1 using neutral substitution rates greater than
1.5 x 10-9 (Figures 4.5B-4.5D). Furthermore, when we considered non-significant
hits, the number of sequences that bore no homology was quite high even when
we used low substitution rates and compared within species that evolve slowly
(i.e. they have low neutral substitution rates) (Figures 4.5B-4.5D). For instance,
-167-

~45% of the human simulated sequences bore no significant homology to human
PV1, using a neutral substitution rate of 1.5 x 10-9 substitutions/site/year (Figure
4.5B). Because we were unable to accurately simulate the process of
neofunctionalization, these percentages likely represent underestimations.
Accumulating evidence supports the notion that the biological activity of tetherin
can be attributed to its unique dual-anchored topology. It is noteworthy that
proteins with a single transmembrane domain N-terminal to coiled-coil domains
comprise only ~0.3% of the annotated human proteome. An even smaller fraction
of these proteins are heterogeneously glycosylated and carry at least one
cysteine residue, features that are well-established to be critical for the antiviral
activity of tetherin. Therefore, it is not too far-fetched to speculate that adjacent
gene products might be related if they share such a rare architecture, and if so,
might even be able to perform the same function. Remarkably, our functional
analyses indeed revealed that PV1 seems to have a modest ability to trap
extracellular HIV-1 virions, and that it is possible to improve this activity when it is
engineered to mimic the dual-anchored architecture of tetherin (Figures 4.6A and
4.6B). Note that a unifying property that is essential for both the cellular function
of PV1 and for the antiviral activity of tetherin is the capacity to dimerize
efficiently. Thus, PV1 might already have an intrinsic antiviral potential that could
easily have been appropriated for adaptation to tetherin. In this regard, we found
that some, but not all, PV1/tetherin-like proteins also share the intrinsic ability to
trap virions, and that this activity is dramatically improved when their cytoplasmic
tails are truncated (Figures 4.7A and 4.7B).
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The identification of the ancestral configuration of the PV1 locus in reptiles and
amphibians reinforces our premise that tetherin is an ancient paralog of PV1. We
concede that it remains formally possible that tetherin arose elsewhere and was
inserted as a single gene into the PV1 ancestral configuration (Figure 4.8).
However, the likelihood of such an event is minimal because (i) the probability of
tetherin being inserted adjacent to another gene with such a rare architecture is
quite low (~200 genes/20,000 human genes), and, (ii) the majority of the PV1-like
gene pairs likely arose via duplication. Even more unlikely is the scenario that
tetherin was inserted precisely next to CILP2 in marsupials and next to PV1 in
eutherians, after originating elsewhere. Further annotation and assembly of the
platypus genome could potentially support our model.
Viral infections impose a potent selection pressure on their hosts and shape their
antiviral strategies. Tetherin continues to co-evolve with modern pathogens, and
in fact, bovids and microbats have two and four copies of tetherin respectively
(Figure 2B). We speculate that the pathogenic burden in these species imposed
the need for a recent expansion of the tetherin locus. In fact, it might very well be
the case that each paralog is antagonized by a subset of viruses, but can inhibit
the rest.
In conclusion, the emergence of tetherin presumably conferred a considerable
selective advantage to its host in the face of ancient retroviral infections, leading
to its rapid fixation in mammals. The acquisition of a GPI anchor might have
empowered natural selection to devise an elegant means of potently inhibiting a
hitherto untargeted step in the life cycle of enveloped viruses, i.e. assembly and
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release. More generally, these findings underscore the incredible capacity of our
genomes to innovate novel functionalities via gene duplication.
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Chapter VI Epilogue
Ode to Tetherin
“My name is tetherin, and my fortunes are on an upward spiral,
For I am an effector of intrinsic immunity; indeed, I am antiviral.
I am the real deal; no charlatan, no actor,
And there are those who would even call me a restriction factor.
So when a virus is sensed, and the time is ripe,
I am induced by interferon in almost any cell type.
I have been fine-tuned by evolution to shackle viruses in their prime.
Discovered by Neil, Guatelli and Bieniasz; been around for a longer time.”

“My amino acid sequence can be wild-type or chimeric,
But in order to be potent, I have to be dimeric.
I have a fascinating topology, and can be designed from scratch,
Just preserve my overall architecture; that virus is no match.
And when you substitute every motif with a heterologous domain,
Behold! Sans homology, my powers do not wane!”

“With an anchor in the cell, and yet another in the virion,
Axially configured, I trap them by the million.
I have a predilection that is not entirely insane,
I’d rather insert my GPI anchor into the viral membrane!
This facilitates endocytosis of the rogues that I hold,
Or, alternatively, I function as a signaling scaffold.”
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“Almost invincible, there is nothing that I cannot thwart,
Except for Vpu, who is an antagonizing sort!
Our battles are grim; signatures of positive selection bear witness,
My nemesis neutralizes me to enhance transmission fitness.
All in all, our struggles always live up to their billing,
My life in genetic conflict- endlessly fulfilling!”
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